This bibliography shows the most interesting papers selected from pmc PubMedCentral which were newly included in covid025P
It is available online and for download at http://www.kidney.de/write/PMCmedVIP_covid025P.html
Skewed: Nephrology, Rheumatology, Immunology, Cell Biology, Research Methods. on-topic and educational Clinical Medicine.
The full table of all monthly collections is: at house-of-papers.com
PMC searches were done at moremed.org





{{tp|p=33515005|t=2021. Habitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank.|pdf=|usr=}}
{{tp|p=33399201|t=2021. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.|pdf=|usr=}}
{{tp|p=33399186|t=2021. Importance of the Lipid-Bound Character of Vitamin D Binding Protein in the Evaluation of Vitamin D Status in COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33483744|t=2021. Developing statewide remdesivir use criteria.|pdf=|usr=}}
{{tp|p=33493729|t=2021. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33410395|t=2021. COVID-19 and Corticosteroids: Unfamiliar but Potentially Fatal Infections That Can Arise following Short-Course Steroid Treatment.|pdf=|usr=}}
{{tp|p=33508271|t=2021. Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies.|pdf=|usr=}}
{{tp|p=33469977|t=2021. Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein.|pdf=|usr=}}
{{tp|p=33464672|t=2021. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.|pdf=|usr=}}
{{tp|p=33387615|t=2021. Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab.|pdf=|usr=}}
{{tp|p=33420963|t=2021. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients.|pdf=|usr=}}
{{tp|p=33395345|t=2021. Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment.|pdf=|usr=}}
{{tp|p=33395339|t=2021. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose.|pdf=|usr=}}
{{tp|p=33460347|t=2021. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.|pdf=|usr=}}
{{tp|p=33456770|t=2021. Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis.|pdf=|usr=}}
{{tp|p=33520220|t=2021. When to call it off: Defining the role of low-dose corticosteroids in thwarting the progression of non-severe COVID-19.|pdf=|usr=}}
{{tp|p=33489115|t=2021. Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33440983|t=2021. Antiviral treatment in COVID-19: which is the most promising?-a narrative review.|pdf=|usr=}}
{{tp|p=33381234|t=2020. Low-dose radiation therapy for coronavirus disease-2019 pneumonia: Is it time to look beyond apprehensions?|pdf=|usr=}}
{{tp|p=33440681|t=2021. Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets.|pdf=|usr=}}
{{tp|p=33401749|t=2021. Role of Melatonin on Virus-Induced Neuropathogenesis-A Concomitant Therapeutic Strategy to Understand SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33515606|t=2021. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.|pdf=|usr=}}
{{tp|p=33444702|t=2021. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.|pdf=|usr=}}
{{tp|p=33422611|t=2021. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.|pdf=|usr=}}
{{tp|p=33512610|t=2021. Apoptosis induced by SARS-CoV-2: can we target it?|pdf=|usr=}}
{{tp|p=33512650|t=2021. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.|pdf=|usr=}}
{{tp|p=33519322|t=2021. Drug repositioning based on similarity constrained probabilistic matrix factorization: COVID-19 as a case study.|pdf=|usr=}}
{{tp|p=33485847|t=2021. Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition.|pdf=|usr=}}
{{tp|p=33483203|t=2020. Reply to "Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19".|pdf=|usr=}}
{{tp|p=33389097|t=2021. Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China.|pdf=|usr=}}
{{tp|p=33485639|t=2020. New COVID-19 Vaccines, Its Cost and Shelf Life: A Cost Effectiveness Analysis.|pdf=|usr=}}
{{tp|p=33380359|t=2020. COVID-19 Vaccines: New Developments and the Road Ahead.|pdf=|usr=}}
{{tp|p=33459817|t=2021. Addressing the potential role of curcumin in the prevention of COVID-19 by targeting the Nsp9 replicase protein through molecular docking.|pdf=|usr=}}
{{tp|p=33398691|t=2021. Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm.|pdf=|usr=}}
{{tp|p=33492523|t=2021. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.|pdf=|usr=}}
{{tp|p=33457430|t=2021. Chemical profiling of selected Ayurveda formulations recommended for COVID-19.|pdf=|usr=}}
{{tp|p=33483287|t=2021. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?|pdf=|usr=}}
{{tp|p=33454058|t=2021. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.|pdf=|usr=}}
{{tp|p=33388129|t=2021. Remdesivir: From Ebola to COVID-19.|pdf=|usr=}}
{{tp|p=33387885|t=2021. In silico study of the potential interactions of 4'-acetamidechalcones with protein targets in SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33477032|t=2021. ATP biphasically modulates LLPS of SARS-CoV-2 nucleocapsid protein and specifically binds its RNA-binding domain.|pdf=|usr=}}
{{tp|p=33515531|t=2021. PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.|pdf=|usr=}}
{{tp|p=33482149|t=2021. Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics.|pdf=|usr=}}
{{tp|p=33439253|t=2021. Antivirals that target the host IMPalpha/beta1-virus interface.|pdf=|usr=}}
{{tp|p=33469510|t=2021. A domain-based vaccine construct against SARS-CoV-2, the causative agent of COVID-19 pandemic: development of self-amplifying mRNA and peptide vaccines.|pdf=|usr=}}
{{tp|p=33381848|t=2020. FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33409924|t=2021. Olfactory Disturbances as Presenting Manifestation Among Egyptian Patients with COVID-19: Possible Role of Zinc.|pdf=|usr=}}
{{tp|p=33513850|t=2021. Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33508618|t=2021. The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33486202|t=2021. Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic.|pdf=|usr=}}
{{tp|p=33378989|t=2021. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.|pdf=|usr=}}
{{tp|p=33486212|t=2021. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=33454595|t=2021. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators.|pdf=|usr=}}
{{tp|p=33426074|t=2020. Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues.|pdf=|usr=}}
{{tp|p=33424013|t=2021. Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit.|pdf=|usr=}}
{{tp|p=33430299|t=2021. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.|pdf=|usr=}}
{{tp|p=33445810|t=2021. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.|pdf=|usr=}}
{{tp|p=33396926|t=2020. Potential Medicinal Plants for the Treatment of Dengue Fever and Severe Acute Respiratory Syndrome-Coronavirus.|pdf=|usr=}}
{{tp|p=33450541|t=2021. Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses.|pdf=|usr=}}
{{tp|p=33515918|t=2021. Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking.|pdf=|usr=}}
{{tp|p=33458647|t=2021. Review of pharmacologic and immunologic agents in the management of COVID-19.|pdf=|usr=}}
{{tp|p=33390423|t=2021. Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19?|pdf=|usr=}}
{{tp|p=33390384|t=2021. Latest updates on COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=33443562|t=2021. Vaccinations in CLL: implications for COVID-19.|pdf=|usr=}}
{{tp|p=33478471|t=2021. Allergen fragrance molecules: a potential relief for COVID-19.|pdf=|usr=}}
{{tp|p=33446136|t=2021. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.|pdf=|usr=}}
{{tp|p=33430799|t=2021. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33413329|t=2021. Computational analysis to repurpose drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33482902|t=2021. A pilot trial of human amniotic fluid for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33472855|t=2021. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.|pdf=|usr=}}
{{tp|p=33419750|t=2021. Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab.|pdf=|usr=}}
{{tp|p=33509890|t=2021. Convalescent plasma for COVID-19 complicated by ARDS due to TRALI.|pdf=|usr=}}
{{tp|p=33472840|t=2021. Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33504571|t=2021. Does vitamin D supplementation prevent SARS-CoV-2 infection in military personnel? Review of the evidence.|pdf=|usr=}}
{{tp|p=33521556|t=2020. Micronutrient deficiencies in patients with COVID-19: how metabolomics can contribute to their prevention and replenishment.|pdf=|usr=}}
{{tp|p=33521536|t=2020. Responsibility for vitamin D supplementation of elderly care home residents in England: falling through the gap between medicine and food.|pdf=|usr=}}
{{tp|p=33441373|t=2021. Rationale for azithromycin in COVID-19: an overview of existing evidence.|pdf=|usr=}}
{{tp|p=33483637|t=2021. Oral side effects of COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33454964|t=2021. Oral ivermectin for a scabies outbreak in a long-term care facility: potential value in preventing COVID-19 and associated mortality.|pdf=|usr=}}
{{tp|p=33524158|t=2021. Convalescent plasma for COVID-19 - encouraging signals of efficacy.|pdf=|usr=}}
{{tp|p=33482025|t=2021. Early mortality benefit with COVID-19 convalescent plasma: a matched control study.|pdf=|usr=}}
{{tp|p=33504378|t=2021. Optimising COVID-19 vaccine efficacy by ensuring nutritional adequacy.|pdf=|usr=}}
{{tp|p=33468263|t=2021. Vitamin A in resistance to and recovery from infection: relevance to SARS-CoV2.|pdf=|usr=}}
{{tp|p=33518836|t=2021. Helmet mask and tocilizumab for a patient with hemophagocytic lymphohistiocytosis syndrome and COVID-19: a case report.|pdf=|usr=}}
{{tp|p=33497434|t=2021. Identifying anti-coronavirus peptides by incorporating different negative datasets and imbalanced learning strategies.|pdf=|usr=}}
{{tp|p=33480398|t=2021. DrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses.|pdf=|usr=}}
{{tp|p=33461215|t=2021. Ligand-based approach for predicting drug targets and for virtual screening against COVID-19.|pdf=|usr=}}
{{tp|p=33406222|t=2021. Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro.|pdf=|usr=}}
{{tp|p=33406218|t=2021. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.|pdf=|usr=}}
{{tp|p=33497123|t=2021. Monoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19.|pdf=|usr=}}
{{tp|p=33517757|t=2021. Clozapine Intoxication in COVID-19.|pdf=|usr=}}
{{tp|p=33439703|t=2021. The Need for Novel Approaches in Assessing the Value of COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33416244|t=2020. Effects of Hydroxychloroquine With or Without Azithromycin on QT Interval in COVID-19: A Systematic Review. Electrophysiology Collaborative Consortium for Meta-analysis-Electram Investigators.|pdf=|usr=}}
{{tp|p=33481405|t=2021. Aspirin in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome: An Old, Low-Cost Therapy With a Strong Rationale.|pdf=|usr=}}
{{tp|p=33395337|t=2021. WHO recommends corticosteroids for patients with severe or critical COVID-19.|pdf=|usr=}}
{{tp|p=33395331|t=2021. In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.|pdf=|usr=}}
{{tp|p=33524290|t=2021. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 >/=7 days after the 2nd dose.|pdf=|usr=}}
{{tp|p=33524282|t=2021. In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon beta-1a differed from standard care for in-hospital mortality.|pdf=|usr=}}
{{tp|p=33524280|t=2021. Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19.|pdf=|usr=}}
{{tp|p=33509798|t=2021. Response to: 'Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'' by Perricone et al.|pdf=|usr=}}
{{tp|p=33509794|t=2021. Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'.|pdf=|usr=}}
{{tp|p=33504481|t=2021. Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'.|pdf=|usr=}}
{{tp|p=33504480|t=2021. Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada.|pdf=|usr=}}
{{tp|p=33452005|t=2021. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.|pdf=|usr=}}
{{tp|p=33459727|t=2020. Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33472834|t=2021. Covid-19: Arthritis drug trial for severe illness is stopped early after increase in deaths.|pdf=|usr=}}
{{tp|p=33446489|t=2021. Covid-19: Convalescent plasma may cut deaths in patients not on ventilation, study indicates.|pdf=|usr=}}
{{tp|p=33436419|t=2021. How the Oxford-AstraZeneca covid-19 vaccine was made.|pdf=|usr=}}
{{tp|p=33455917|t=2021. Cyclosporine: hope for severe COVID-19?|pdf=|usr=}}
{{tp|p=33401333|t=2021. COVID-19 and the revival of passive immunization: Antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31.|pdf=|usr=}}
{{tp|p=33512003|t=2021. Neurological risks and benefits of cytokine-based treatments in coronavirus disease 2019: from preclinical to clinical evidence.|pdf=|usr=}}
{{tp|p=33502877|t=2021. Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19?|pdf=|usr=}}

{{tp|p=33521606|t=2021. Antiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: Mini review.|pdf=|usr=}}
{{tp|p=33481336|t=2021. Generation of enzymatically competent SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered Nicotiana benthamiana.|pdf=|usr=}}
{{tp|p=33430659|t=2021. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.|pdf=|usr=}}
{{tp|p=33513419|t=2021. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.|pdf=|usr=}}
{{tp|p=33485971|t=2021. Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification.|pdf=|usr=}}
{{tp|p=33485973|t=2021. Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.|pdf=|usr=}}
{{tp|p=33514385|t=2021. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.|pdf=|usr=}}
{{tp|p=33426604|t=2021. ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy.|pdf=|usr=}}
{{tp|p=33403500|t=2021. Pharmacotherapeutics of SARS-CoV-2 Infections.|pdf=|usr=}}
{{tp|p=33491033|t=2021. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey.|pdf=|usr=}}
{{tp|p=33491026|t=2021. Editorial: COVID19 Vaccination in Frail People. Lots of Hope and Some Questions.|pdf=|usr=}}
{{tp|p=33398242|t=2021. Potential therapeutic approaches of microRNAs for COVID-19: Challenges and opportunities.|pdf=|usr=}}
{{tp|p=33456225|t=2020. A brief outlook on the current emerging trends of COVID 19 vaccines.|pdf=|usr=}}
{{tp|p=33388760|t=2021. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents.|pdf=|usr=}}
{{tp|p=33495677|t=2021. Comments on potential re-purposing of medicines against high-altitude illnesses towards SARS-CoV2: possibilities and pitfalls.|pdf=|usr=}}
{{tp|p=33472369|t=2021. ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33439850|t=2021. Diet, Nutrition, Obesity, and Their Implications for COVID-19 Mortality: Development of a Marginalized Two-Part Model for Semicontinuous Data.|pdf=|usr=}}
{{tp|p=33437926|t=2021. A Call to Action: "Low-Dose Radiation May Help Cure COVID-19..." [Taps Mic] "...Is This Thing On?"|pdf=|usr=}}
{{tp|p=33437924|t=2021. Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls.|pdf=|usr=}}
{{tp|p=33390434|t=2020. Increased secondary infection in COVID-19 patients treated with steroids in New York City.|pdf=|usr=}}
{{tp|p=33485468|t=2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.|pdf=|usr=}}
{{tp|p=33485467|t=2021. Optimism and caution for an inactivated COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33493450|t=2021. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.|pdf=|usr=}}
{{tp|p=33493449|t=2021. The right place for IL-1 inhibition in COVID-19.|pdf=|usr=}}
{{tp|p=33484632|t=2021. Realising the potential of SARS-CoV-2 vaccines-a long shot?|pdf=|usr=}}
{{tp|p=33460572|t=2021. Assessing the importance of interleukin-6 in COVID-19 - Authors' reply.|pdf=|usr=}}
{{tp|p=33460569|t=2021. Assessing the importance of interleukin-6 in COVID-19.|pdf=|usr=}}
{{tp|p=33461387|t=2021. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.|pdf=|usr=}}
{{tp|p=33476632|t=2021. Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model.|pdf=|usr=}}
{{tp|p=33513400|t=2021. Cardiovascular protective properties of oxytocin against COVID-19.|pdf=|usr=}}
{{tp|p=33402630|t=2021. Is there a role for inhaled ciclesonide in the treatment of COVID-19?|pdf=|usr=}}
{{tp|p=33513822|t=2021. Caged Dexamethasone/Quercetin Nanoparticles, Formed of the Morphogenetic Active Inorganic Polyphosphate, are Strong Inducers of MUC5AC.|pdf=|usr=}}
{{tp|p=33413833|t=2021. Inverse Relationship of Maximal Exercise Capacity to Hospitalization Secondary to Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33413825|t=2021. Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma.|pdf=|usr=}}
{{tp|p=33413824|t=2021. In Reply - Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma.|pdf=|usr=}}
{{tp|p=33419872|t=2021. Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV.|pdf=|usr=}}
{{tp|p=33468703|t=2021. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro.|pdf=|usr=}}
{{tp|p=33424100|t=2020. Physical Activity Outdoors as an Alternative to Lockdown: the Three Cs Strategy.|pdf=|usr=}}
{{tp|p=33388144|t=2021. Reaccion transfusional a plasma hiperinmune en pacientes con infeccion grave por COVID-19.|pdf=|usr=}}
{{tp|p=33380371|t=2021. Efectividad de los glucocorticoides en pacientes hospitalizados por neumonia grave por SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33392390|t=2021. Relationship between MMR vaccination and severity of Covid-19 infection. Survey among primary care physicians.|pdf=|usr=}}
{{tp|p=33422363|t=2021. Tackling the COVID-19 "cytokine storm" with microRNA mimics directly targeting the 3'UTR of pro-inflammatory mRNAs.|pdf=|usr=}}
{{tp|p=33385879|t=2021. Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced "cytokines storm".|pdf=|usr=}}
{{tp|p=33385878|t=2021. The plausible mechanisms of tramadol for treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33485026|t=2021. Daylight is critical to preserve 5-methoxytryptophol levels in suspected and confirmed COVID-19 patients.|pdf=|usr=}}
{{tp|p=33482620|t=2021. Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy.|pdf=|usr=}}
{{tp|p=33460992|t=2021. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.|pdf=|usr=}}
{{tp|p=33421690|t=2021. Platelet hyperactivity in COVID-19: Can the tomato extract Fruitflow(R) be used as an antiplatelet regime?|pdf=|usr=}}
{{tp|p=33505216|t=2021. Exploring the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids.|pdf=|usr=}}
{{tp|p=33481741|t=2020. La bioseguridad de las vacunas anti-COVID-19.|pdf=|usr=}}
{{tp|p=33481727|t=2020. Plasma de convalecientes como terapia para la neumonia por COVID-19 grave.|pdf=|usr=}}
{{tp|p=33429732|t=2021. Anti-IL6 treatment of serious COVID-19 disease: A monocentric retrospective experience.|pdf=|usr=}}
{{tp|p=33453392|t=2021. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.|pdf=|usr=}}
{{tp|p=33482357|t=2021. Could targeting immunometabolism be a way to control the burden of COVID-19 infection?|pdf=|usr=}}
{{tp|p=33430200|t=2021. Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections.|pdf=|usr=}}
{{tp|p=33451069|t=2021. Development of Coronavirus Treatments Using Neutralizing Antibodies.|pdf=|usr=}}
{{tp|p=33402220|t=2021. SARS-CoV-2: vaccines in the pandemic era.|pdf=|usr=}}
{{tp|p=33464512|t=2021. Anaphylaxie-Risiko bei der COVID-19-Impfung: Empfehlungen fur das praktische Management.|pdf=|usr=}}
{{tp|p=33507892|t=2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.|pdf=|usr=}}
{{tp|p=33444297|t=2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.|pdf=|usr=}}
{{tp|p=33382675|t=2021. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.|pdf=|usr=}}
{{tp|p=33464543|t=2021. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).|pdf=|usr=}}
{{tp|p=33400086|t=2021. COVID-19: inflammatory responses, structure-based drug design and potential therapeutics.|pdf=|usr=}}
{{tp|p=33400085|t=2021. First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery.|pdf=|usr=}}
{{tp|p=33398633|t=2021. Identification of novel inhibitors of angiotensin-converting enzyme 2 (ACE-2) receptor from Urtica dioica to combat coronavirus disease 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33389560|t=2021. CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy.|pdf=|usr=}}
{{tp|p=33389441|t=2021. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.|pdf=|usr=}}
{{tp|p=33492566|t=2021. Computational assessment of saikosaponins as adjuvant treatment for COVID-19: molecular docking, dynamics, and network pharmacology analysis.|pdf=|usr=}}
{{tp|p=33389440|t=2021. Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study.|pdf=|usr=}}
{{tp|p=33503834|t=2021. Antiviral Activity of Jamaican Medicinal Plants and Isolated Bioactive Compounds.|pdf=|usr=}}
{{tp|p=33467029|t=2021. Natural and Nature-Derived Products Targeting Human Coronaviruses.|pdf=|usr=}}
{{tp|p=33466743|t=2021. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.|pdf=|usr=}}
{{tp|p=33500564|t=2021. The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes.|pdf=|usr=}}
{{tp|p=33471984|t=2021. Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection.|pdf=|usr=}}
{{tp|p=33440088|t=2021. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.|pdf=|usr=}}
{{tp|p=33440086|t=2021. (A Little) Clarity on Convalescent Plasma for Covid-19.|pdf=|usr=}}
{{tp|p=33406353|t=2021. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.|pdf=|usr=}}
{{tp|p=33391623|t=2020. Manganese nanodepot augments host immune response against coronavirus.|pdf=|usr=}}
{{tp|p=33418136|t=2021. iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome.|pdf=|usr=}}
{{tp|p=33510133|t=2021. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.|pdf=|usr=}}
{{tp|p=33483491|t=2021. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.|pdf=|usr=}}
{{tp|p=33473140|t=2021. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape.|pdf=|usr=}}
{{tp|p=33473130|t=2021. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery.|pdf=|usr=}}
{{tp|p=33446655|t=2021. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.|pdf=|usr=}}
{{tp|p=33436624|t=2021. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.|pdf=|usr=}}
{{tp|p=33436577|t=2021. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.|pdf=|usr=}}
{{tp|p=33436573|t=2021. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.|pdf=|usr=}}
{{tp|p=33431876|t=2021. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.|pdf=|usr=}}
{{tp|p=33431856|t=2021. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.|pdf=|usr=}}
{{tp|p=33432129|t=2021. Immune readouts from the Oxford COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33394134|t=2021. NF-kappaB signalling as a pharmacological target in COVID-19: potential roles for IKKbeta inhibitors.|pdf=|usr=}}
{{tp|p=33416933|t=2021. Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?|pdf=|usr=}}
{{tp|p=33443616|t=2021. Efficacy of synthetic glucocorticoids in COVID-19 endothelites.|pdf=|usr=}}
{{tp|p=33425362|t=2021. Oral probiotics in coronavirus disease 2019: connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials.|pdf=|usr=}}
{{tp|p=33495468|t=2021. Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters.|pdf=|usr=}}
{{tp|p=33495451|t=2021. The double-sided effects of Mycobacterium Bovis bacillus Calmette-Guerin vaccine.|pdf=|usr=}}
{{tp|p=33435521|t=2021. Magnesium in Infectious Diseases in Older People.|pdf=|usr=}}
{{tp|p=33498631|t=2021. Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro.|pdf=|usr=}}
{{tp|p=33466642|t=2021. Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study.|pdf=|usr=}}
{{tp|p=33419325|t=2020. Nutritional and Behavioral Approaches to Body Composition and Low-Grade Chronic Inflammation Management for Older Adults in the Ordinary and COVID-19 Times.|pdf=|usr=}}
{{tp|p=33412367|t=2021. Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases.|pdf=|usr=}}
{{tp|p=33456092|t=2021. COVID-19: Analysis of Drug Repositioning Practice.|pdf=|usr=}}
{{tp|p=33445955|t=2021. Repurposing drugs during the COVID-19 pandemic and beyond.|pdf=|usr=}}
{{tp|p=33430081|t=2021. Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection.|pdf=|usr=}}
{{tp|p=33419184|t=2021. Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33455739|t=2021. Inmunomodulacion mediante CONVEHY(R) para COVID-19: de la tormenta al anticiclon de citoquinas.|pdf=|usr=}}
{{tp|p=33493900|t=2021. Carrying out pseudo dual nucleic acid detection from sample to visual result in a polypropylene bag with CRISPR/Cas12a.|pdf=|usr=}}
{{tp|p=33419743|t=2021. Covid-19: Arthritis drugs improve survival in intensive care patients, shows study.|pdf=|usr=}}
{{tp|p=33408068|t=2021. Covid-19 vaccination: What's the evidence for extending the dosing interval?|pdf=|usr=}}
{{tp|p=33514589|t=2021. Increasing recruitment into covid-19 trials.|pdf=|usr=}}
{{tp|p=33428504|t=2021. Formulation and stability study of hydroxychloroquine sulfate oral suspensions.|pdf=|usr=}}
{{tp|p=33497594|t=2021. The Potential Role of Photobiomodulation in Long COVID-19 Patients Rehabilitation.|pdf=|usr=}}

{{tp|p=33476998|t=2021. Predictive value of the prognostic nutritional index for the severity of coronavirus disease 2019.|pdf=|usr=}}
{{tp|p=33450678|t=2021. Micronutrients and bioactive substances: Their potential roles in combating COVID-19.|pdf=|usr=}}
{{tp|p=33421827|t=2021. Sarcopenia: An underlying treatment target during the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33418230|t=2021. Increased risk for COVID-19 in patients with vitamin D deficiency.|pdf=|usr=}}
{{tp|p=33426364|t=2021. Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33408570|t=2020. Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials.|pdf=|usr=}}
{{tp|p=33426262|t=2021. Matched cohort study on the efficacy of tocilizumab in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33506065|t=2021. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients.|pdf=|usr=}}
{{tp|p=33425070|t=2020. BCG Vaccine does not Protect Against COVID-19.|pdf=|usr=}}
{{tp|p=33456654|t=2020. Use of tocilizumab in a patient with severe COVID-19 in a Teaching Hospital in Ghana: a case report.|pdf=|usr=}}
{{tp|p=33456653|t=2020. Promotion of unproved and potential dangerous measures in fighting COVID-19 pandemic: urgent need for vigilant appropriate public communication and generation of scientific evidence.|pdf=|usr=}}
{{tp|p=33425157|t=2020. A review of COVID-19 vaccines in development: 6 months into the pandemic.|pdf=|usr=}}
{{tp|p=33480519|t=2021. Why two doses of the BNT162b2 mRNA Covid-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA Covid-19 and other vaccines.|pdf=|usr=}}
{{tp|p=33504008|t=2021. Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach.|pdf=|usr=}}
{{tp|p=33477294|t=2021. COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33435273|t=2021. Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters.|pdf=|usr=}}
{{tp|p=33437147|t=2021. Effects on LOS may not justify cost of remdesivir for severe COVID-19.|pdf=|usr=}}
{{tp|p=33389725|t=2021. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.|pdf=|usr=}}
{{tp|p=33389724|t=2021. SARS-CoV-2 therapeutics: how far do we stand from a remedy?|pdf=|usr=}}
{{tp|p=33421347|t=2021. Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.|pdf=|usr=}}
{{tp|p=33515763|t=2021. A combination of phototherapy modalities for extensive lip lesions in a patient with SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33422697|t=2021. Can photodynamic therapy be repurposed to treat oral lesions of COVID-19?|pdf=|usr=}}
{{tp|p=33463909|t=2021. 17beta-estradiol reduces SARS-CoV-2 infection in vitro.|pdf=|usr=}}
{{tp|p=33485605|t=2020. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle.|pdf=|usr=}}
{{tp|p=33380375|t=2020. Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?|pdf=|usr=}}
{{tp|p=33419674|t=2020. Effects and safety of herbal medicines among community-dwelling residents during COVID-19 pandemic: A large prospective, randomized controlled trial (RCT).|pdf=|usr=}}
{{tp|p=33495692|t=2021. Localized Plasmonic Photothermal Therapy as a Life-saving Treatment Paradigm for Hospitalized COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33382685|t=2020. A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro.|pdf=|usr=}}
{{tp|p=33395417|t=2021. Zinc against COVID-19? Symptom surveillance and deficiency risk groups.|pdf=|usr=}}
{{tp|p=33507958|t=2021. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response.|pdf=|usr=}}
{{tp|p=33497420|t=2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study.|pdf=|usr=}}
{{tp|p=33493227|t=2021. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein.|pdf=|usr=}}
{{tp|p=33481950|t=2021. Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice.|pdf=|usr=}}
{{tp|p=33444408|t=2021. Quercetin as a potential treatment for COVID-19-induced acute kidney injury: Based on network pharmacology and molecular docking study.|pdf=|usr=}}
{{tp|p=33417604|t=2021. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2).|pdf=|usr=}}
{{tp|p=33411791|t=2021. Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study.|pdf=|usr=}}
{{tp|p=33406138|t=2021. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.|pdf=|usr=}}
{{tp|p=33382734|t=2020. The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study.|pdf=|usr=}}
{{tp|p=33465165|t=2021. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.|pdf=|usr=}}
{{tp|p=33382547|t=2021. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study.|pdf=|usr=}}
{{tp|p=33481361|t=2020. Polymers with antiviral properties: A brief review.|pdf=|usr=}}
{{tp|p=33481360|t=2020. Focus on COVID-19: Antiviral polymers in drugs and vaccines.|pdf=|usr=}}
{{tp|p=33452205|t=2021. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33390763|t=2021. Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients.|pdf=|usr=}}
{{tp|p=33516093|t=2021. Blood omega-3 fatty acids and death from COVID-19: A pilot study.|pdf=|usr=}}
{{tp|p=33420956|t=2021. Pan-coronavirus fusion inhibitors as the hope for today and tomorrow.|pdf=|usr=}}
{{tp|p=33387249|t=2021. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.|pdf=|usr=}}
{{tp|p=33392622|t=2021. Fluvoxamine, melatonin and COVID-19.|pdf=|usr=}}
{{tp|p=33465426|t=2021. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients.|pdf=|usr=}}
{{tp|p=33489300|t=2020. Vitamin D and COVID-19: evidence and recommendations for supplementation.|pdf=|usr=}}
{{tp|p=33415646|t=2021. Potential Role of Zinc in the COVID-19 Disease Process and its Probable Impact on Reproduction.|pdf=|usr=}}
{{tp|p=33461535|t=2021. Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.|pdf=|usr=}}
{{tp|p=33399672|t=2020. Corticoides para el tratamiento de COVID-19.|pdf=|usr=}}
{{tp|p=33388902|t=2021. Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33386447|t=2021. COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.|pdf=|usr=}}
{{tp|p=33447107|t=2021. Effects of Vitamin D on COVID-19 Infection and Prognosis: A Systematic Review.|pdf=|usr=}}
{{tp|p=33458569|t=2021. Re-reading ACT, BCG, and Low COVID-19 in Africa.|pdf=|usr=}}
{{tp|p=33503560|t=2021. Molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-2 molecule (2E)-N-methyl-2-[(4-oxo-4H-chromen-3-yl)methylidene]-hydrazinecarbothioamide (Dimer) - quantum chemical approach.|pdf=|usr=}}
{{tp|p=33514427|t=2021. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.|pdf=|usr=}}
{{tp|p=33511519|t=2021. Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying miRNA as a Potential Multi Target Therapy to COVID-19: an In Silico Analysis.|pdf=|usr=}}
{{tp|p=33511518|t=2021. Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment.|pdf=|usr=}}
{{tp|p=33432484|t=2021. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.|pdf=|usr=}}
{{tp|p=33423157|t=2021. Stem Cells as Potential Therapeutics and Targets for Infection by COVID19 - Special Issue on COVID19 in Stem Cell Reviews and Reports.|pdf=|usr=}}
{{tp|p=33415541|t=2021. Dimethyl Fumarate Can Enhance the Potential Therapeutic Effects of Epidermal Neural Crest Stem Cells in COVID-19 Patients.|pdf=|usr=}}
{{tp|p=33414832|t=2020. Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2.|pdf=|usr=}}
{{tp|p=33400390|t=2021. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.|pdf=|usr=}}
{{tp|p=33502567|t=2021. COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two cases.|pdf=|usr=}}
{{tp|p=33437137|t=2021. Combination and tricombination therapy to destabilize the structural integrity of COVID-19 by some bioactive compounds with antiviral drugs: insights from molecular docking study.|pdf=|usr=}}
{{tp|p=33382449|t=2020. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.|pdf=|usr=}}
{{tp|p=33408775|t=2021. The 2020 race towards SARS-CoV-2 specific vaccines.|pdf=|usr=}}
{{tp|p=33391531|t=2021. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.|pdf=|usr=}}
{{tp|p=33391497|t=2021. Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein.|pdf=|usr=}}
{{tp|p=33433109|t=2021. Kortikosteroider til sykehjemspasienter med covid-19?|pdf=|usr=}}
{{tp|p=33428032|t=2021. Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33484708|t=2021. Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress.|pdf=|usr=}}
{{tp|p=33425684|t=2021. Nicotinic cholinergic system and COVID-19: In silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions.|pdf=|usr=}}
{{tp|p=33478889|t=2021. A look-back at convalescent plasma to treat COVID-19.|pdf=|usr=}}
{{tp|p=33461918|t=2021. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.|pdf=|usr=}}
{{tp|p=33388249|t=2021. The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.|pdf=|usr=}}
{{tp|p=33462569|t=2021. The Intersection of Photopheresis and COVID-19 Vaccination.|pdf=|usr=}}
{{tp|p=33515686|t=2021. Could shear stress mimetics delay complications in COVID-19?|pdf=|usr=}}
{{tp|p=33424125|t=2021. Polysaccharides obtained from natural edible sources and their role in modulating the immune system: Biologically active potential that can be exploited against COVID-19.|pdf=|usr=}}
{{tp|p=33446406|t=2021. Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time.|pdf=|usr=}}
{{tp|p=33505872|t=2021. Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.|pdf=|usr=}}
{{tp|p=33441235|t=2021. Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines.|pdf=|usr=}}
{{tp|p=33478794|t=2021. Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2).|pdf=|usr=}}
{{tp|p=33478787|t=2021. Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.|pdf=|usr=}}
{{tp|p=33429880|t=2021. Current State of the First COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33406785|t=2021. SARS-CoV-2/COVID-19 Vaccines: The Promises and the Challenges Ahead.|pdf=|usr=}}
{{tp|p=33513693|t=2021. COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population.|pdf=|usr=}}
{{tp|p=33499326|t=2021. Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy.|pdf=|usr=}}
{{tp|p=33494530|t=2021. Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate.|pdf=|usr=}}
{{tp|p=33494381|t=2021. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses.|pdf=|usr=}}
{{tp|p=33478109|t=2021. Nanomaterial Delivery Systems for mRNA Vaccines.|pdf=|usr=}}
{{tp|p=33440794|t=2021. Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?|pdf=|usr=}}
{{tp|p=33440640|t=2021. SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33396667|t=2020. Plant-Based Drugs and Vaccines for COVID-19.|pdf=|usr=}}
{{tp|p=33394351|t=2020. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.|pdf=|usr=}}
{{tp|p=33421743|t=2021. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.|pdf=|usr=}}
{{tp|p=33387788|t=2021. Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2.|pdf=|usr=}}
{{tp|p=33503819|t=2021. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.|pdf=|usr=}}
{{tp|p=33498923|t=2021. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL(pro) Inhibitors.|pdf=|usr=}}
{{tp|p=33477902|t=2021. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.|pdf=|usr=}}
{{tp|p=33477376|t=2021. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.|pdf=|usr=}}
{{tp|p=33466921|t=2021. Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design.|pdf=|usr=}}
{{tp|p=33451132|t=2021. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.|pdf=|usr=}}
{{tp|p=33396343|t=2020. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.|pdf=|usr=}}
{{tp|p=33396594|t=2020. PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity.|pdf=|usr=}}
{{tp|p=33396578|t=2020. Interferon-alpha2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities.|pdf=|usr=}}
{{tp|p=33425204|t=2021. Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases.|pdf=|usr=}}
{{tp|p=33386950|t=2021. COVID-19 and BCG: where's the challenge?|pdf=|usr=}}
{{tp|p=33438061|t=2021. Impfung gegen SARS-CoV-2 bei entzundlich rheumatischen Erkrankungen : Empfehlungen der DGRh fur Arzte und Patienten.|pdf=|usr=}}

{{tp|p=33440401|t=2021. Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses.|pdf=|usr=}}
{{tp|p=33386025|t=2021. Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach.|pdf=|usr=}}
{{tp|p=33456058|t=2021. Les vaccins a ARN anti-COVID-19.|pdf=|usr=}}
{{tp|p=33495684|t=2021. Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak.|pdf=|usr=}}
{{tp|p=33503163|t=2021. Reacoes adversas a medicamentos em pacientes com COVID-19 no Brasil: analise das notificacoes espontaneas do sistema de farmacovigilancia brasileiro.|pdf=|usr=}}
{{tp|p=33404925|t=2021. Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm.|pdf=|usr=}}
{{tp|p=33387252|t=2021. QTc Prolongation in COVID-19 Patients Using Chloroquine.|pdf=|usr=}}
{{tp|p=33425407|t=2020. The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis.|pdf=|usr=}}
{{tp|p=33425279|t=2020. Plasmapheresis with corticosteroids and antiviral: a life-saving treatment for severe cases of Covid 19.|pdf=|usr=}}
{{tp|p=33425262|t=2020. A brief review of the latest pharmacological treatments of COVID-19.|pdf=|usr=}}
{{tp|p=33479399|t=2021. COVID-19 vaccines: where we stand and challenges ahead.|pdf=|usr=}}
{{tp|p=33421384|t=2021. The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19.|pdf=|usr=}}
{{tp|p=33488836|t=2021. Engineered Aptamers for Enhanced COVID-19 Theranostics.|pdf=|usr=}}
{{tp|p=33521696|t=2021. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.|pdf=|usr=}}
{{tp|p=33473156|t=2021. Dalbavancin: novel candidate for COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33522308|t=2021. Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.|pdf=|usr=}}
{{tp|p=33502716|t=2021. Effective treatment with Tocilizumab in a COVID-19 patient on maintenance hemodialysis: A case report.|pdf=|usr=}}
{{tp|p=33462575|t=2021. Mass spectrometry reveals potential of beta-lactams as SARS-CoV-2 M(pro) inhibitors.|pdf=|usr=}}
{{tp|p=33424029|t=2021. Synthetic strategies for pyrrolo[2,1-f][1,2,4]triazine: the parent moiety of antiviral drug remdesivir.|pdf=|usr=}}
{{tp|p=33519023|t=2021. Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease.|pdf=|usr=}}
{{tp|p=33518774|t=2021. Exploring the new potential antiviral constituents of Moringa oliefera for SARS-COV-2 pathogenesis: An in silico molecular docking and dynamic studies.|pdf=|usr=}}
{{tp|p=33518775|t=2020. Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: A molecular docking study.|pdf=|usr=}}
{{tp|p=33518858|t=2020. Structure features of peptide-type SARS-CoV main protease inhibitors: Quantitative structure activity relationship study.|pdf=|usr=}}
{{tp|p=33453180|t=2021. A Reserve System for the Equitable Allocation of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.|pdf=|usr=}}
{{tp|p=33493441|t=2021. Surfactant for the Treatment of ARDS in a Patient With Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33422222|t=2021. Zinc and Coronavirus Disease 2019: Causal or Casual Association?|pdf=|usr=}}
{{tp|p=33420601|t=2021. Chinese Medicine in Fighting against Covid-19: Role and Inspiration.|pdf=|usr=}}
{{tp|p=33489151|t=2021. Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.|pdf=|usr=}}
{{tp|p=33521390|t=2021. Antivirals for COVID-19: A critical review.|pdf=|usr=}}
{{tp|p=33486146|t=2021. Unilateral axillary Adenopathy in the setting of COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33429060|t=2021. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases".|pdf=|usr=}}
{{tp|p=33515458|t=2021. Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model.|pdf=|usr=}}
{{tp|p=33515255|t=2021. The Olympiad of SARS-CoV-2 vaccinology: Fundamentals to Complement Technical Frontiers.|pdf=|usr=}}
{{tp|p=33515253|t=2021. Tocilizumab in COVID-19: Give it time!|pdf=|usr=}}
{{tp|p=33515252|t=2021. The impact of vaccination on COVID-19 outbreaks in the United States.|pdf=|usr=}}
{{tp|p=33503230|t=2021. The case against delaying SARS-CoV-2 mRNA vaccine boosting doses.|pdf=|usr=}}
{{tp|p=33503229|t=2021. Antioxidant therapy in COVID-19: The crucial role of early treatment and antioxidant typology.|pdf=|usr=}}
{{tp|p=33502467|t=2021. Accelerate COVID-19 Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines.|pdf=|usr=}}
{{tp|p=33493302|t=2021. Making sense of contradictory evidence in Covid-19 trials.|pdf=|usr=}}
{{tp|p=33402859|t=2020. Early Experience With Methylprednisolone on SARS-CoV-2 Infection in the African American Population, a Retrospective Analysis.|pdf=|usr=}}
{{tp|p=33476807|t=2021. Prophylaxis for COVID-19: a systematic review.|pdf=|usr=}}
{{tp|p=33380357|t=2020. Association between iron status and the risk of adverse outcomes in COVID-19.|pdf=|usr=}}
{{tp|p=33487301|t=2021. Nutritional status assessment in patients with Covid-19 after discharge from the intensive care unit.|pdf=|usr=}}
{{tp|p=33487263|t=2021. Anthropometric assessment in ambulatory nutrition amid the COVID-19 pandemic: Possibilities for the remote and in-person care.|pdf=|usr=}}
{{tp|p=33402269|t=2021. Optimal Timing for COVID-19 Vaccination in Oncology Patients Receiving Chemotherapy?|pdf=|usr=}}
{{tp|p=33501997|t=2021. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33406317|t=2021. Rationale for Effective Prophylaxis Against COVID-19 Through Simultaneous Blockade of Both Endosomal and Non-Endosomal SARS-CoV-2 Entry into Host Cell.|pdf=|usr=}}
{{tp|p=33520676|t=2021. Spectroscopic investigation on the affinity of SARS-CoV-2 spike protein to gold nano-particles.|pdf=|usr=}}
{{tp|p=33520528|t=2020. High Dose Steroid Therapy to Prevent Severe Hypoxia in COVID-19 Patients: A Potential Solution for Low Resource Clinical Setting.|pdf=|usr=}}
{{tp|p=33486832|t=2021. Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19.|pdf=|usr=}}
{{tp|p=33406308|t=2021. Cutaneous manifestations of COVID-19: An unusual presentation with edematous plaques and pruritic, erythematous papules, and comment on the role of bradykinin storm and its therapeutic implications.|pdf=|usr=}}
{{tp|p=33403227|t=2020. Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.|pdf=|usr=}}
{{tp|p=33402882|t=2020. Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China.|pdf=|usr=}}
{{tp|p=33496060|t=2021. Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.|pdf=|usr=}}
{{tp|p=33499310|t=2021. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.|pdf=|usr=}}
{{tp|p=33494244|t=2021. Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination.|pdf=|usr=}}
{{tp|p=33451007|t=2021. Favipiravir in Therapy of Viral Infections.|pdf=|usr=}}
{{tp|p=33447309|t=2020. COVID-19 and Possible Pharmacological Preventive Options.|pdf=|usr=}}
{{tp|p=33426360|t=2020. Anti-tumor necrosis factor agents and COVID-19: A word of caution.|pdf=|usr=}}
{{tp|p=33450319|t=2021. Development of nanoparticle-delivery systems for antiviral agents: A review.|pdf=|usr=}}
{{tp|p=33439960|t=2021. Critical analysis on the use of cholecalciferol as a COVID-19 intervention: a narrative review.|pdf=|usr=}}
{{tp|p=33424398|t=2021. In silico evaluation of flavonoids as effective antiviral agents on the spike glycoprotein of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33424377|t=2021. Probiotics, prebiotics, and COVID-19 infection: A review article.|pdf=|usr=}}
{{tp|p=33457042|t=2021. A large-scale transcriptional study reveals inhibition of COVID-19 related cytokine storm by traditional chinese medicines.|pdf=|usr=}}
{{tp|p=33471276|t=2021. Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19.|pdf=|usr=}}
{{tp|p=33441564|t=2021. Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection.|pdf=|usr=}}
{{tp|p=33420186|t=2021. ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19.|pdf=|usr=}}
{{tp|p=33483539|t=2021. First principle simulation of coated hydroxychloroquine on Ag, Au and Pt nanoparticles.|pdf=|usr=}}
{{tp|p=33479401|t=2021. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies.|pdf=|usr=}}
{{tp|p=33479261|t=2021. Autumn COVID-19 surge dates in Europe correlated to latitudes, not to temperature-humidity, pointing to vitamin D as contributing factor.|pdf=|usr=}}
{{tp|p=33446817|t=2021. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages.|pdf=|usr=}}
{{tp|p=33441985|t=2021. Contact residue contributions to interaction energies between SARS-CoV-1 spike proteins and human ACE2 receptors.|pdf=|usr=}}
{{tp|p=33441909|t=2021. Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33436985|t=2021. Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2.|pdf=|usr=}}
{{tp|p=33436946|t=2021. The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination: a robust ecological analysis using unsupervised machine learning.|pdf=|usr=}}
{{tp|p=33425427|t=2020. Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (M(pro)) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study.|pdf=|usr=}}
{{tp|p=33514688|t=2021. Constrained surfaces: promising therapeutic targets for COVID-19 determined by systematically mutational analysis.|pdf=|usr=}}
{{tp|p=33423577|t=2021. A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19.|pdf=|usr=}}
{{tp|p=33457315|t=2020. The Many Faces of Covid-19: Organizing Pneumonia (OP) Pattern HRCT Features.|pdf=|usr=}}
{{tp|p=33504502|t=2021. Covid-19 controversies: the tocilizumab chapter.|pdf=|usr=}}
{{tp|p=33500251|t=2021. Covid-19: Moderna plans booster doses to counter variants.|pdf=|usr=}}
{{tp|p=33483332|t=2021. Covid-19: Reports from Israel suggest one dose of Pfizer vaccine could be less effective than expected.|pdf=|usr=}}
{{tp|p=33381648|t=2020. Letter to the Editor: Possible Drug-Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs.|pdf=|usr=}}
{{tp|p=33445938|t=2020. Ročni obdobi, vitamin D a COVID-19.|pdf=|usr=}}
{{tp|p=33386649|t=2021. Novel quantitative structure-activity relationship model to predict activities of natural products against COVID-19.|pdf=|usr=}}
{{tp|p=33443248|t=2021. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates.|pdf=|usr=}}
{{tp|p=33524090|t=2021. Antiviral drug discovery: preparing for the next pandemic.|pdf=|usr=}}
{{tp|p=33434052|t=2021. DAMPening Mortality in COVID-19: Therapeutic Insights From Basic Cardiometabolic Studies on S100A8/A9.|pdf=|usr=}}
{{tp|p=33394522|t=2021. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients.|pdf=|usr=}}
{{tp|p=33480877|t=2021. Convalescent Plasma: Education and Administration Implications.|pdf=|usr=}}
{{tp|p=33480870|t=2021. COVID-19 Vaccines: Preparing for Vaccination in the Context of Clinical Oncology Care.|pdf=|usr=}}
{{tp|p=33410139|t=2021. Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID-19 Therapeutics.|pdf=|usr=}}
{{tp|p=33410134|t=2021. Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics.|pdf=|usr=}}
{{tp|p=33480424|t=2021. Host cell glutamine metabolism as a potential antiviral target.|pdf=|usr=}}
{{tp|p=33404204|t=2021. Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33404133|t=2021. Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study.|pdf=|usr=}}
{{tp|p=33403775|t=2021. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.|pdf=|usr=}}
{{tp|p=33441063|t=2021. Deep learning in the quest for compound nomination for fighting COVID-19.|pdf=|usr=}}
{{tp|p=33509001|t=2021. The nutritional status of the elderly patient infected with COVID-19: the forgotten risk factor?|pdf=|usr=}}
{{tp|p=33504301|t=2021. Phenylbenzopyrone of flavonoids as a potential scaffold to prevent SARS-CoV-2 replication by inhibiting its MPRO main protease.|pdf=|usr=}}
{{tp|p=33459226|t=2021. Therapeutic agents against COVID-19 with clinical evidence.|pdf=|usr=}}
{{tp|p=33459225|t=2021. Natural agents modulating ACE-2: A review of compounds with potential against SARS-CoV-2 infections.|pdf=|usr=}}
{{tp|p=33430748|t=2021. In silico Prediction and Designing of Potential siRNAs to be Used as Antivirals Against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33430746|t=2021. Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical based Evidence.|pdf=|usr=}}
{{tp|p=33388014|t=2021. Use of Natural Compounds as a potential therapeutic agent against COVID-19.|pdf=|usr=}}
{{tp|p=33438550|t=2021. Regenerative Medicine Approaches in COVID -19 Pneumonia.|pdf=|usr=}}
{{tp|p=33463470|t=2021. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.|pdf=|usr=}}
{{tp|p=33497492|t=2021. A finding associated with favipiravir-associated photosensitivity: Yellow-green fluorescence in the lunulae, scalp, and face.|pdf=|usr=}}
{{tp|p=33517789|t=2021. Study on mechanism of matrine in treatment of COVID-19 combined with liver injury by network pharmacology and molecular docking technology.|pdf=|usr=}}
{{tp|p=33401328|t=2021. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis.|pdf=|usr=}}
{{tp|p=33513649|t=2021. Steroide in der Infektionsmedizin.|pdf=|usr=}}
{{tp|p=33459251|t=2021. The Role of Nutrition during the COVID-19 Pandemic: What We Know.|pdf=|usr=}}

{{tp|p=33520579|t=2021. Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.|pdf=|usr=}}
{{tp|p=33500874|t=2021. Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19).|pdf=|usr=}}
{{tp|p=33457176|t=2021. Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis.|pdf=|usr=}}
{{tp|p=33457172|t=2021. Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches.|pdf=|usr=}}
{{tp|p=33457171|t=2021. In silico docking analysis revealed the potential of phytochemicals present in Phyllanthus amarus and Andrographis paniculata, used in Ayurveda medicine in inhibiting SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33417425|t=2021. Early Returns on Small Molecule Therapeutics for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33479570|t=2021. Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33480671|t=2021. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles.|pdf=|usr=}}
{{tp|p=33464829|t=2021. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.|pdf=|usr=}}
{{tp|p=33398250|t=2020. Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease.|pdf=|usr=}}
{{tp|p=33456449|t=2021. Complexity analysis of cold chain transportation in a vaccine supply chain considering activity inspection and time-delay.|pdf=|usr=}}
{{tp|p=33422546|t=2021. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33421475|t=2021. Recombinant protein vaccines, a proven approach against coronavirus pandemics.|pdf=|usr=}}
{{tp|p=33400957|t=2021. Self-assembled mRNA vaccines.|pdf=|usr=}}
{{tp|p=33428995|t=2021. Nanocarrier vaccines for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33482248|t=2021. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?|pdf=|usr=}}
{{tp|p=33465451|t=2021. In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives.|pdf=|usr=}}
{{tp|p=33491915|t=2021. Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity.|pdf=|usr=}}
{{tp|p=33458958|t=2021. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.|pdf=|usr=}}
{{tp|p=33520645|t=2021. Vitamin-D and COVID-19: time for the profession to take a stand.|pdf=|usr=}}
{{tp|p=33520646|t=2020. The potential contribution of traditional, complementary and integrative treatments in acute viral respiratory tract infections: Rapid Reviews in response to the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33439972|t=2021. Western Dietary Pattern Antioxidant Intakes and Oxidative Stress: Importance During the SARS-CoV-2/COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33471354|t=2021. A review of Ciclesonide in COVID-19. Still a long way to go.|pdf=|usr=}}
{{tp|p=33393643|t=2020. Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience.|pdf=|usr=}}
{{tp|p=33465050|t=2021. Fighting the storm: could novel anti-TNFalpha and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19?|pdf=|usr=}}
{{tp|p=33489449|t=2020. TaibUVID nutritional supplements help rapid cure of COVID-19 infection and rapid reversion to negative nasopharyngeal swab PCR: for better public prophylaxis and treatment of COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33415017|t=2020. Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease.|pdf=|usr=}}
{{tp|p=33417877|t=2021. Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19.|pdf=|usr=}}
{{tp|p=33489475|t=2020. Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33502950|t=2021. Soluble ACE2 as a potential therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33404354|t=2021. Exploring the link between vitamin D and clinical outcomes in COVID-19.|pdf=|usr=}}
{{tp|p=33404365|t=2021. Remote ischemic conditioning for acute respiratory distress syndrome in COVID-19.|pdf=|usr=}}
{{tp|p=33496642|t=2020. Potential role for nitazoxanide in treating SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33437355|t=2020. Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade?|pdf=|usr=}}
{{tp|p=33397585|t=2021. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.|pdf=|usr=}}
{{tp|p=33484986|t=2021. Potential beneficial role of probiotics on the outcome of COVID-19 patients: An evolving perspective.|pdf=|usr=}}
{{tp|p=33390567|t=2021. Analytical methods for the determination of remdesivir as a promising antiviral candidate drug for the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33385574|t=2021. Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions.|pdf=|usr=}}
{{tp|p=33422991|t=2021. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.|pdf=|usr=}}
{{tp|p=33418497|t=2021. Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19.|pdf=|usr=}}
{{tp|p=33495752|t=2021. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.|pdf=|usr=}}
{{tp|p=33521339|t=2021. Multiple sclerosis, B cell therapy, and the COVID-19 vaccine.|pdf=|usr=}}
{{tp|p=33520331|t=2020. The Scientific Foundation of Chinese Herbal Medicine against COVID-19.|pdf=|usr=}}
{{tp|p=33472816|t=2021. Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?|pdf=|usr=}}
{{tp|p=33520016|t=2021. COVID-19, prevention and treatment with herbal medicine in the herbal markets of Sale Prefecture, North-Western Morocco.|pdf=|usr=}}
{{tp|p=33520014|t=2021. Two pronged approach for prevention and therapy of COVID-19 (Sars-CoV-2) by a multi-targeted herbal drug, a component of ayurvedic decoction.|pdf=|usr=}}
{{tp|p=33520015|t=2020. Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools.|pdf=|usr=}}
{{tp|p=33524687|t=2021. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33508085|t=2021. Is COVID-19 lockdown associated with vitamin D deficiency?|pdf=|usr=}}
{{tp|p=33506949|t=2021. Quinacrine as a potential treatment for COVID-19 virus infection.|pdf=|usr=}}
{{tp|p=33506948|t=2021. Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.|pdf=|usr=}}
{{tp|p=33506946|t=2021. Remdesivir as a broad-spectrum antiviral drug against COVID-19.|pdf=|usr=}}
{{tp|p=33504238|t=2021. Tocilizumab for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33475441|t=2021. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.|pdf=|usr=}}
{{tp|p=33499687|t=2021. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.|pdf=|usr=}}
{{tp|p=33435759|t=2021. Immunoinformatics-guided designing and in silico analysis of epitope-based polyvalent vaccines against multiple strains of human coronavirus (HCoV).|pdf=|usr=}}
{{tp|p=33435774|t=2021. COVID-19 vaccine: where are we now and where should we go?|pdf=|usr=}}
{{tp|p=33443475|t=2021. Remdesivir y reduccion de mortalidad en pacientes con COVID-19: analisis sistematizado de subgrupos de los ensayos clinicos.|pdf=|usr=}}
{{tp|p=33449359|t=2021. Dynamics and electrostatics define an allosteric druggable site within the receptor-binding domain of SARS-CoV-2 spike protein.|pdf=|usr=}}
{{tp|p=33520970|t=2020. Perinatal Cells: A Promising COVID-19 Therapy?|pdf=|usr=}}
{{tp|p=33520943|t=2020. In silico Analysis Revealed Potential Anti-SARS-CoV-2 Main Protease Activity by the Zonulin Inhibitor Larazotide Acetate.|pdf=|usr=}}
{{tp|p=33521056|t=2020. In vitro Dissolution Profile at Different Biological pH Conditions of Hydroxychloroquine Sulfate Tablets Is Available for the Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33521032|t=2020. Predictive Value of Prognostic Nutritional Index on COVID-19 Severity.|pdf=|usr=}}
{{tp|p=33472895|t=2021. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.|pdf=|usr=}}
{{tp|p=33462654|t=2021. Impfempfehlungen der Standigen Impfkommission (STIKO) : Impfungen bei Immundefizienz und Impfung gegen COVID-19.|pdf=|usr=}}
{{tp|p=33482433|t=2021. Is prognostic nutritional index a predictive marker for estimating all-cause in-hospital mortality in COVID-19 patients with cardiovascular risk factors?|pdf=|usr=}}
{{tp|p=33467131|t=2021. Can Optimum Solar Radiation Exposure or Supplemented Vitamin D Intake Reduce the Severity of COVID-19 Symptoms?|pdf=|usr=}}
{{tp|p=33524396|t=2021. Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33416020|t=2021. Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets.|pdf=|usr=}}
{{tp|p=33413032|t=2021. Identification of potential SARS-CoV-2 M(pro) inhibitors integrating molecular docking and water thermodynamics.|pdf=|usr=}}
{{tp|p=33403946|t=2021. In silico design of multi-epitope-based peptide vaccine against SARS-CoV-2 using its spike protein.|pdf=|usr=}}
{{tp|p=33509045|t=2021. Applying high throughput and comprehensive immunoinformatics approaches to design a trivalent subunit vaccine for induction of immune response against emerging human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33491579|t=2021. Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19.|pdf=|usr=}}
{{tp|p=33491569|t=2021. RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2.|pdf=|usr=}}
{{tp|p=33427102|t=2021. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.|pdf=|usr=}}
{{tp|p=33474735|t=2021. AAMC Discusses Monoclonal Antibody Therapeutics for SARS-CoV-2 Infection.|pdf=|usr=}}
{{tp|p=33511638|t=2021. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review.|pdf=|usr=}}
{{tp|p=33491508|t=2021. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro.|pdf=|usr=}}
{{tp|p=33442304|t=2021. Experimental Pharmacotherapy for COVID-19: The Latest Advances.|pdf=|usr=}}
{{tp|p=33391636|t=2020. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus.|pdf=|usr=}}
{{tp|p=33458853|t=2021. Potential health benefits of zinc supplementation for the management of COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33380377|t=2020. Vaccine efficacy against COVID-19: A foresight on the host-associated factors.|pdf=|usr=}}
{{tp|p=33519145|t=2021. Evaluating the potency of Sulawesi propolis compounds as ACE-2 inhibitors through molecular docking for COVID-19 drug discovery preliminary study.|pdf=|usr=}}
{{tp|p=33519144|t=2021. Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review.|pdf=|usr=}}
{{tp|p=33464639|t=2021. Role of vitamin D in regulating COVID-19 severity-An immunological perspective.|pdf=|usr=}}
{{tp|p=33523654|t=2021. Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.|pdf=|usr=}}
{{tp|p=33512007|t=2021. Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease.|pdf=|usr=}}
{{tp|p=33503267|t=2021. Oxygen-ozone autohemotherapy against COVID-19 needs to fit highly experienced, customized, and standardized protocols to succeed.|pdf=|usr=}}
{{tp|p=33475170|t=2021. Zinc treatment of outpatient COVID-19: A retrospective review of 28 consecutive patients.|pdf=|usr=}}
{{tp|p=33475167|t=2021. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.|pdf=|usr=}}
{{tp|p=33511655|t=2021. Early remdesivir treatment in COVID-19: Why wait another day?|pdf=|usr=}}
{{tp|p=33448426|t=2021. Clinical efficacy of Methylprednisolone and the combined use of Lopinavir/Ritonavir with Arbidol in treatment of Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33493301|t=2021. Available drugs and supplements for rapid deployment for treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33516966|t=2021. A potential solution to avoid overdose of mixed drugs in the event of Covid-19: Nanomedicine at the heart of the Covid-19 pandemic.|pdf=|usr=}}
{{tp|p=33518856|t=2021. A computational approach for the screening of potential antiviral compounds against SARS-CoV-2 protease: Ionic liquid vs herbal and natural compounds.|pdf=|usr=}}
{{tp|p=33518854|t=2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part II: Complexation with several pi-acceptors (PA, CLA, CHL).|pdf=|usr=}}
{{tp|p=33395259|t=2021. Antiviral Activity of 7-Substituted 7-Deazapurine Ribonucleosides, Monophosphate Prodrugs, and Triphoshates against Emerging RNA Viruses.|pdf=|usr=}}
{{tp|p=33468299|t=2021. Vacina para a COVID-19: Da Teoria a Pratica.|pdf=|usr=}}
{{tp|p=33523540|t=2021. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.|pdf=|usr=}}
{{tp|p=33504509|t=2021. Is sitagliptin effective for the treatment of COVID-19?|pdf=|usr=}}
{{tp|p=33386655|t=2021. Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective.|pdf=|usr=}}
{{tp|p=33423554|t=2021. SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development.|pdf=|usr=}}
{{tp|p=33400393|t=2021. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.|pdf=|usr=}}
{{tp|p=33448695|t=2020. Vitamin D to prevent COVID-19: recommendations for the design of clinical trials.|pdf=|usr=}}
{{tp|p=33491580|t=2021. Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling.|pdf=|usr=}}
{{tp|p=33491573|t=2021. Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.|pdf=|usr=}}
{{tp|p=33459176|t=2021. Molecular docking and simulation studies of natural compounds of Vitex negundo L. against papain-like protease (PL(pro)) of SARS CoV-2 (coronavirus) to conquer the pandemic situation in the world.|pdf=|usr=}}
{{tp|p=33459174|t=2021. Withanolides from Withania somnifera as an immunity booster and their therapeutic options against COVID-19.|pdf=|usr=}}
{{tp|p=33433137|t=2021. Pandemic aspect of dexamethasone: Molecular mechanisms and clinical application.|pdf=|usr=}}
{{tp|p=33504214|t=2021. A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33507143|t=2021. Targeting novel structural and functional features of coronavirus protease nsp5 (3CL(pro), M(pro)) in the age of COVID-19.|pdf=|usr=}}
{{tp|p=33386773|t=2021. SARS-CoV-2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice.|pdf=|usr=}}

{{tp|p=33426632|t=2021. COVID-19 vaccination in immunocompromised patients.|pdf=|usr=}}
{{tp|p=33503192|t=2021. Antiviral activity of Brazilian Green Propolis extract against SARS-CoV-2 (Severe Acute Respiratory Syndrome - Coronavirus 2) infection: case report and review.|pdf=|usr=}}
{{tp|p=33504561|t=2021. Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making.|pdf=|usr=}}
{{tp|p=33408097|t=2021. Remdesivir for patients with COVID-19.|pdf=|usr=}}
{{tp|p=33473151|t=2021. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.|pdf=|usr=}}
{{tp|p=33505639|t=2021. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.|pdf=|usr=}}
{{tp|p=33398234|t=2021. Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering.|pdf=|usr=}}
{{tp|p=33391634|t=2021. Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33391633|t=2021. Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity?|pdf=|usr=}}
{{tp|p=33422642|t=2021. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=}}
{{tp|p=33495742|t=2021. Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol.|pdf=|usr=}}
{{tp|p=33397463|t=2021. Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study.|pdf=|usr=}}
{{tp|p=33490955|t=2021. Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis.|pdf=|usr=}}
{{tp|p=33437559|t=2021. Influenza Vaccination Quality Improvement as a Model for COVID-19 Prophylaxis.|pdf=|usr=}}
{{tp|p=33425565|t=2021. The Flu Vaccination May Have a Protective Effect on the Course of COVID-19 in the Pediatric Population: When Does Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Meet Influenza?|pdf=|usr=}}
{{tp|p=33409034|t=2020. Treatment Experience With Inhaled Corticosteroids in Combination with Remdesivir and Dexamethasone Among COVID-19 Patients Admitted to a Rural Community Hospital: A Case Series.|pdf=|usr=}}
{{tp|p=33409026|t=2020. The Role of Vitamin C as Adjuvant Therapy in COVID-19.|pdf=|usr=}}
{{tp|p=33510989|t=2020. Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale.|pdf=|usr=}}
{{tp|p=33489621|t=2020. Is There any Additional Benefit of Multiple Doses of Tocilizumab in COVID-19 Patients?|pdf=|usr=}}
{{tp|p=33475900|t=2021. Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.|pdf=|usr=}}
{{tp|p=33409442|t=2020. COVID-19 and Telenutrition: Remote Consultation in Clinical Nutrition Practice.|pdf=|usr=}}
{{tp|p=33390762|t=2021. Exogenous pulmonary surfactant: A review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added clinical marker.|pdf=|usr=}}
{{tp|p=33403480|t=2021. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor.|pdf=|usr=}}
{{tp|p=33457366|t=2020. Treatment of Crimean-Congo Haemorrhagic Fever by Favipiravir in a Patient with Novel Coronavirus Co-Infection.|pdf=|usr=}}
{{tp|p=33415491|t=2021. A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.|pdf=|usr=}}
{{tp|p=33439342|t=2021. A novel approach to managing COVID-19 patients: results of lopinavir plus doxycycline cohort-authors' reply.|pdf=|usr=}}
{{tp|p=33404753|t=2021. Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.|pdf=|usr=}}
{{tp|p=33452110|t=2021. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.|pdf=|usr=}}
{{tp|p=33425074|t=2021. Network pharmacology-based analysis of Zukamu granules for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33423905|t=2021. Flying higher than politics: The goal of preventive medicine at the time of the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33486200|t=2021. The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33483798|t=2021. Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33464367|t=2021. Severe sinus bradycardia associated with remdesivir in a child with severe SARS-COV-2 infection-reply.|pdf=|usr=}}
{{tp|p=33428898|t=2021. Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33387467|t=2021. Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations.|pdf=|usr=}}
{{tp|p=33482181|t=2021. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.|pdf=|usr=}}
{{tp|p=33497607|t=2021. Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2.|pdf=|usr=}}
{{tp|p=33509962|t=2021. Is high-dose glucocorticoid beneficial in COVID-19?|pdf=|usr=}}
{{tp|p=33511068|t=2020. Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh.|pdf=|usr=}}
{{tp|p=33381197|t=2020. Screening for a Potential Therapeutic Agent from the Herbal Formula in the 4(th) Edition of the Chinese National Guidelines for the Initial-Stage Management of COVID-19 via Molecular Docking.|pdf=|usr=}}
{{tp|p=33500777|t=2020. Option-based guarantees to accelerate urgent, high-risk vaccines: a new market-shaping approach.|pdf=|usr=}}
{{tp|p=33495727|t=2021. Polyphenols as promising biologically active substances for preventing SARS-CoV-2: A review with research evidence and underlying mechanisms.|pdf=|usr=}}
{{tp|p=33418408|t=2021. An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33412235|t=2021. Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study.|pdf=|usr=}}
{{tp|p=33435315|t=2021. Probiotic Effects against Virus Infections: New Weapons for an Old War.|pdf=|usr=}}
{{tp|p=33475983|t=2021. Does herbal therapy for COVID-19 have implications for forensic practice?|pdf=|usr=}}
{{tp|p=33469529|t=2020. Nitric Oxide Releasing Hydrogel Nanoparticles Decreases Epithelial Cell Injuries Associated With Airway Reopening.|pdf=|usr=}}
{{tp|p=33426009|t=2020. Investigating the Potential for Ultraviolet Light to Modulate Morbidity and Mortality From COVID-19: A Narrative Review and Update.|pdf=|usr=}}
{{tp|p=33392268|t=2020. Thromboinflammation and COVID-19: The Role of Exercise in the Prevention and Treatment.|pdf=|usr=}}
{{tp|p=33469541|t=2020. Combating COVID-19 With Mesenchymal Stem/Stromal Cell Therapy: Promise and Challenges.|pdf=|usr=}}
{{tp|p=33384971|t=2020. NOX-Dependent Signaling Dysregulation in Severe COVID-19: Clues to Effective Treatments.|pdf=|usr=}}
{{tp|p=33381464|t=2020. What Can Cellular Redox, Iron, and Reactive Oxygen Species Suggest About the Mechanisms and Potential Therapy of COVID-19?|pdf=|usr=}}
{{tp|p=33425850|t=2020. Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33488592|t=2020. Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33424848|t=2020. COVID-19: Coronavirus Vaccine Development Updates.|pdf=|usr=}}
{{tp|p=33424838|t=2020. The Artificial-Liver Blood-Purification System Can Effectively Improve Hypercytokinemia for COVID-19.|pdf=|usr=}}
{{tp|p=33408715|t=2020. Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-19.|pdf=|usr=}}
{{tp|p=33391285|t=2020. A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters.|pdf=|usr=}}
{{tp|p=33425942|t=2020. Humidified Warmed CO2 Treatment Therapy Strategies Can Save Lives With Mitigation and Suppression of SARS-CoV-2 Infection: An Evidence Review.|pdf=|usr=}}
{{tp|p=33415116|t=2020. The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective.|pdf=|usr=}}
{{tp|p=33490110|t=2020. Molecular Docking and Molecular Dynamics Aided Virtual Search of OliveNet Directory for Secoiridoids to Combat SARS-CoV-2 Infection and Associated Hyperinflammatory Responses.|pdf=|usr=}}
{{tp|p=33425995|t=2020. Exploring the Potential of Carbon Dots to Combat COVID-19.|pdf=|usr=}}
{{tp|p=33425994|t=2020. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL(pro).|pdf=|usr=}}
{{tp|p=33392263|t=2020. The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic.|pdf=|usr=}}
{{tp|p=33392261|t=2020. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening.|pdf=|usr=}}
{{tp|p=33381519|t=2020. Potential Mechanisms for Traditional Chinese Medicine in Treating Airway Mucus Hypersecretion Associated With Coronavirus Disease 2019.|pdf=|usr=}}
{{tp|p=33505983|t=2020. Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study.|pdf=|usr=}}
{{tp|p=33385008|t=2020. Probiotics as a Weapon in the Fight Against COVID-19.|pdf=|usr=}}
{{tp|p=33489899|t=2020. COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.|pdf=|usr=}}
{{tp|p=33447586|t=2020. Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome.|pdf=|usr=}}
{{tp|p=33442386|t=2020. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.|pdf=|usr=}}
{{tp|p=33424586|t=2020. Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-COV-2 Infection.|pdf=|usr=}}
{{tp|p=33390999|t=2020. Commentary: Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report.|pdf=|usr=}}
{{tp|p=33390994|t=2020. COVID-19 Disease and Vitamin D: A Mini-Review.|pdf=|usr=}}
{{tp|p=33390974|t=2020. Hydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review.|pdf=|usr=}}
{{tp|p=33390967|t=2020. Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review.|pdf=|usr=}}
{{tp|p=33390952|t=2020. Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2.|pdf=|usr=}}
{{tp|p=33390948|t=2020. The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.|pdf=|usr=}}
{{tp|p=33384605|t=2020. Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=}}
{{tp|p=33505321|t=2020. Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial.|pdf=|usr=}}
{{tp|p=33424618|t=2020. The Effects of Displacing Sedentary Behavior With Two Distinct Patterns of Light Activity on Health Outcomes in Older Adults (Implications for COVID-19 Quarantine).|pdf=|usr=}}
{{tp|p=33490659|t=2021. Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19?|pdf=|usr=}}
{{tp|p=33462562|t=2021. Traditional foods with their constituent's antiviral and immune system modulating properties.|pdf=|usr=}}
{{tp|p=33458435|t=2021. In silico validation of potent phytochemical orientin as inhibitor of SARS-CoV-2 spike and host cell receptor GRP78 binding.|pdf=|usr=}}
{{tp|p=33421583|t=2021. Impact of colchicine on mortality in patients with COVID-19: A meta-analysis.|pdf=|usr=}}
{{tp|p=33473017|t=2021. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial.|pdf=|usr=}}
{{tp|p=33448317|t=2021. Vitamin D, zinc and glutamine: Synergistic action with OncoTherad immunomodulator in interferon signaling and COVID19 (Review).|pdf=|usr=}}
{{tp|p=33491759|t=2021. Immune-checkpoint inhibitors from cancer to COVID19: A promising avenue for the treatment of patients with COVID19 (Review).|pdf=|usr=}}
{{tp|p=33523564|t=2021. Emerging COVID-19 vaccines: A rheumatology perspective.|pdf=|usr=}}
{{tp|p=33517559|t=2021. Adverse drug reactions in SARS-COV-2 hospitalised patients: a case series with a focus on drug-drug interactions-comment.|pdf=|usr=}}
{{tp|p=33521604|t=2021. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.|pdf=|usr=}}
{{tp|p=33388478|t=2020. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.|pdf=|usr=}}
{{tp|p=33524876|t=2021. COVID-19 convalescent plasma composition and immunological effects in severe patients.|pdf=|usr=}}
{{tp|p=33519133|t=2021. An Open Clinical Evaluation Of Selected Siddha Regimen In Expediting The Management Of Covid-19 -A Randomized Controlled Study.|pdf=|usr=}}
{{tp|p=33519134|t=2020. Pathophysiology of COVID-19 and Host centric approaches of Ayurveda.|pdf=|usr=}}
{{tp|p=33518853|t=2021. Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33518802|t=2021. In silico assessment and sonochemical synthesis of 2-alkynyl 3-chloropyrazines as prospective ligands for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33518801|t=2021. Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19.|pdf=|usr=}}
{{tp|p=33518803|t=2021. Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies.|pdf=|usr=}}
{{tp|p=33493479|t=2021. Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model.|pdf=|usr=}}
{{tp|p=33523655|t=2021. Retrained Generic Antibodies Can Recognize SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33508197|t=2021. On Drug-Membrane Permeability of Antivirals for SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33439735|t=2021. Butyrate Regulates COVID-19-Relevant Genes in Gut Epithelial Organoids From Normotensive Rats.|pdf=|usr=}}
{{tp|p=33406943|t=2021. Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility.|pdf=|usr=}}
{{tp|p=33390092|t=2021. The impact of probiotics on interactions within the microbiota-gut-lung triad in COVID-19.|pdf=|usr=}}
{{tp|p=33435749|t=2021. Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19.|pdf=|usr=}}
{{tp|p=33488303|t=2020. Opportunities for Health Promotion: Highlighting Herbs and Spices to Improve Immune Support and Well-being.|pdf=|usr=}}
{{tp|p=33500022|t=2021. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.|pdf=|usr=}}
{{tp|p=33510536|t=2021. COVID-19 Vaccine Development to Vaccination.|pdf=|usr=}}
{{tp|p=33509969|t=2021. LETTER TO THE EDITOR: ON POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19.|pdf=|usr=}}
{{tp|p=33483330|t=2021. COVID-19 Vaccination: An Overview and Education Tool for Nuclear Medicine Technologists.|pdf=|usr=}}
{{tp|p=33455524|t=2021. Clinical Consideration of Glucocorticoids in COVID-19.|pdf=|usr=}}

{{tp|p=33447376|t=2020. Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.|pdf=|usr=}}
{{tp|p=33447372|t=2020. Computational screening for potential drug candidates against the SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33519469|t=2020. Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives.|pdf=|usr=}}
{{tp|p=33519467|t=2020. 3-Hydroxyphthalic Anhydride-Modified Chicken Ovalbumin as a Potential Candidate Inhibits SARS-CoV-2 Infection by Disrupting the Interaction of Spike Protein With Host ACE2 Receptor.|pdf=|usr=}}
{{tp|p=33519463|t=2020. TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target.|pdf=|usr=}}
{{tp|p=33519460|t=2020. Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19.|pdf=|usr=}}
{{tp|p=33519449|t=2020. A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection.|pdf=|usr=}}
{{tp|p=33490124|t=2020. The Strategy of Boosting the Immune System Under the COVID-19 Pandemic.|pdf=|usr=}}
{{tp|p=33457429|t=2021. Compounds of Citrus medica and Zingiber officinale for COVID-19 inhibition: in silico evidence for cues from Ayurveda.|pdf=|usr=}}
{{tp|p=33415989|t=2021. Can natural products stop the SARS-CoV-2 virus? A docking and molecular dynamics study of a natural product database.|pdf=|usr=}}
{{tp|p=33404263|t=2020. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33432269|t=2020. Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective.|pdf=|usr=}}
{{tp|p=33387518|t=2021. Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19.|pdf=|usr=}}
{{tp|p=33484690|t=2021. Reply: The New Foe and Old Friends: Are We Ready for Microbiota-based Therapeutics in Treating COVID-19 Patients?|pdf=|usr=}}
{{tp|p=33453230|t=2021. Reply.|pdf=|usr=}}
{{tp|p=33388317|t=2020. Letter to the editor: Famotidine and mortality in COVID-19.|pdf=|usr=}}
{{tp|p=33387529|t=2020. Famotidine and COVID-19.|pdf=|usr=}}
{{tp|p=33487665|t=2021. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding.|pdf=|usr=}}
{{tp|p=33428154|t=2021. Screening druggable targets and predicting therapeutic drugs for COVID-19 via integrated bioinformatics analysis.|pdf=|usr=}}
{{tp|p=33413610|t=2021. An integrated in silico immuno-genetic analytical platform provides insights into COVID-19 serological and vaccine targets.|pdf=|usr=}}
{{tp|p=33482326|t=2021. Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy.|pdf=|usr=}}
{{tp|p=33412759|t=2020. Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33432441|t=2021. PI3K/AKT signaling pathway: a possible target for adjuvant therapy in COVID-19.|pdf=|usr=}}
{{tp|p=33386081|t=2021. Network machine learning maps phytochemically rich "Hyperfoods" to fight COVID-19.|pdf=|usr=}}
{{tp|p=33426490|t=2021. Editorial Comment to Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone.|pdf=|usr=}}
{{tp|p=33465283|t=2021. Efficacy of canakinumab in mild or severe COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33418320|t=2021. BCG immunomodulation: From the 'hygiene hypothesis' to COVID-19.|pdf=|usr=}}
{{tp|p=33492637|t=2021. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.|pdf=|usr=}}
{{tp|p=33397150|t=2021. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.|pdf=|usr=}}
{{tp|p=33432283|t=2021. Evaluation of certain medicinal plants compounds as new potential inhibitors of novel corona virus (COVID-19) using molecular docking analysis.|pdf=|usr=}}
{{tp|p=33425648|t=2021. In silico investigation of saponins and tannins as potential inhibitors of SARS-CoV-2 main protease (M(pro)).|pdf=|usr=}}
{{tp|p=33425647|t=2021. Designing a conserved peptide-based subunit vaccine against SARS-CoV-2 using immunoinformatics approach.|pdf=|usr=}}
{{tp|p=33437070|t=2020. Hyperbaric oxygen therapy: Can it be a novel supportive therapy in COVID-19?|pdf=|usr=}}
{{tp|p=33495676|t=2021. COVID-19 and Gut Microbiota: A Potential Connection.|pdf=|usr=}}
{{tp|p=33384519|t=2020. Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials.|pdf=|usr=}}
{{tp|p=33384506|t=2020. A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital.|pdf=|usr=}}
{{tp|p=33384504|t=2020. Immunomodulation and COVID-19: Is There a Winning Combination?|pdf=|usr=}}
{{tp|p=33446983|t=2020. Intravenous Immunoglobulin may Reverse Multisystem Inflammation in COVID-19 Pneumonitis and Guillain-Barre Syndrome.|pdf=|usr=}}
{{tp|p=33424043|t=2021. Restoring Good Health in Elderly with Diverse Gut Microbiome and Food Intake Restriction to Combat COVID-19.|pdf=|usr=}}
{{tp|p=33390627|t=2020. Recent Clinical Trials on Natural Products and Traditional Chinese Medicine Combating the COVID-19.|pdf=|usr=}}
{{tp|p=33469896|t=2021. BCG Vaccination Protection Against COVID-19: Correspondence.|pdf=|usr=}}
{{tp|p=33484407|t=2021. The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort.|pdf=|usr=}}
{{tp|p=33500636|t=2021. Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease.|pdf=|usr=}}
{{tp|p=33422682|t=2021. Identification of SARS-CoV-2 CTL epitopes for development of a multivalent subunit vaccine for COVID-19.|pdf=|usr=}}
{{tp|p=33495884|t=2021. Worldwide inverse correlation between Bacille Calmette-Guerin (BCG) immunization and COVID-19 mortality.|pdf=|usr=}}
{{tp|p=33389708|t=2021. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.|pdf=|usr=}}
{{tp|p=33521241|t=2021. Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease.|pdf=|usr=}}
{{tp|p=33457495|t=2021. In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19).|pdf=|usr=}}
{{tp|p=33521757|t=2021. Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir.|pdf=|usr=}}
{{tp|p=33524979|t=2021. Principles and Challenges in anti-COVID-19 Vaccine Development.|pdf=|usr=}}
{{tp|p=33476982|t=2021. Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review.|pdf=|usr=}}
{{tp|p=33450596|t=2021. Different characteristics of critical COVID-19 and thinking of treatment strategies in non-elderly and elderly severe adult patients.|pdf=|usr=}}
{{tp|p=33429331|t=2021. The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.|pdf=|usr=}}
{{tp|p=33418248|t=2021. Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target.|pdf=|usr=}}
{{tp|p=33412395|t=2021. Combination therapy of IFNbeta1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.|pdf=|usr=}}
{{tp|p=33421928|t=2021. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study).|pdf=|usr=}}
{{tp|p=33515687|t=2021. Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals.|pdf=|usr=}}
{{tp|p=33476734|t=2021. Reply to the letter to the editor "Azithromycin, treatment in COVID-19".|pdf=|usr=}}
{{tp|p=33476733|t=2021. Azithromycin, a questionable treatment for COVID-19.|pdf=|usr=}}
{{tp|p=33400975|t=2021. Passive immunization and its rebirth in the era of the COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33408033|t=2021. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.|pdf=|usr=}}
{{tp|p=33408032|t=2021. Advanced statistical methods and designs for clinical trials for COVID-19.|pdf=|usr=}}
{{tp|p=33408031|t=2021. Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.|pdf=|usr=}}
{{tp|p=33408029|t=2021. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.|pdf=|usr=}}
{{tp|p=33408028|t=2021. Response to advances statistical methods and designs for clinical trials for COVID-19.|pdf=|usr=}}
{{tp|p=33408027|t=2021. Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.|pdf=|usr=}}
{{tp|p=33408026|t=2021. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.|pdf=|usr=}}
{{tp|p=33408025|t=2021. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.|pdf=|usr=}}
{{tp|p=33408024|t=2021. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".|pdf=|usr=}}
{{tp|p=33408022|t=2021. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.|pdf=|usr=}}
{{tp|p=33408021|t=2021. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".|pdf=|usr=}}
{{tp|p=33408020|t=2021. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.|pdf=|usr=}}
{{tp|p=33408019|t=2021. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.|pdf=|usr=}}
{{tp|p=33408018|t=2021. Doxycycline as an Alternative to Azithromycin in Elderly Patients.|pdf=|usr=}}
{{tp|p=33408017|t=2021. Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.|pdf=|usr=}}
{{tp|p=33405321|t=2021. Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis.|pdf=|usr=}}
{{tp|p=33417696|t=2021. Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma.|pdf=|usr=}}
{{tp|p=33411937|t=2021. Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer.|pdf=|usr=}}
{{tp|p=33433587|t=2021. Nature and dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19.|pdf=|usr=}}
{{tp|p=33511686|t=2021. Tocilizumab in COVID-19 interstitial pneumonia.|pdf=|usr=}}
{{tp|p=33520685|t=2021. Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach.|pdf=|usr=}}
{{tp|p=33520684|t=2021. Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods.|pdf=|usr=}}
{{tp|p=33520683|t=2021. Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection.|pdf=|usr=}}
{{tp|p=33520682|t=2021. Molecular docking analysis of rutin reveals possible inhibition of SARS-CoV-2 vital proteins.|pdf=|usr=}}
{{tp|p=33521616|t=2021. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.|pdf=|usr=}}
{{tp|p=33480414|t=2021. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?|pdf=|usr=}}
{{tp|p=33516648|t=2021. Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study.|pdf=|usr=}}
{{tp|p=33521397|t=2021. Integrating Integrins: A New Way to Increase Our COVID-19 Armamentarium?|pdf=|usr=}}
{{tp|p=33518628|t=2021. Inactivation of SARS-CoV-2 by Catechins from Green Tea.|pdf=|usr=}}
{{tp|p=33518623|t=2021. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.|pdf=|usr=}}
{{tp|p=33524312|t=2021. Next-generation COVID-19 vaccines: here come the proteins.|pdf=|usr=}}
{{tp|p=33524311|t=2021. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.|pdf=|usr=}}
{{tp|p=33521772|t=2021. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.|pdf=|usr=}}
{{tp|p=33521771|t=2021. Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?|pdf=|usr=}}
{{tp|p=33521768|t=2020. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults.|pdf=|usr=}}
{{tp|p=33521732|t=2021. COVID-19 vaccines: the pandemic will not end overnight.|pdf=|usr=}}
{{tp|p=33463480|t=2021. The Role of Justicia Adhatoda as prophylaxis for COVID-19 - Analysis based on docking study.|pdf=|usr=}}
{{tp|p=33493866|t=2021. Ergosterol peroxide exhibits antiviral and immunomodulatory abilities against porcine deltacoronavirus (PDCoV) via suppression of NF-kappaB and p38/MAPK signaling pathways in vitro.|pdf=|usr=}}
{{tp|p=33414160|t=2021. Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins.|pdf=|usr=}}
{{tp|p=33414159|t=2021. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.|pdf=|usr=}}
{{tp|p=33468542|t=2021. The time for COVID-19 vaccination.|pdf=|usr=}}
{{tp|p=33441348|t=2021. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33507218|t=2021. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.|pdf=|usr=}}
{{tp|p=33404587|t=2021. Sorting Out Whether Vitamin D Deficiency Raises COVID-19 Risk.|pdf=|usr=}}
{{tp|p=33464336|t=2021. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.|pdf=|usr=}}
{{tp|p=33404585|t=2021. Problems With Paying People to Be Vaccinated Against COVID-19.|pdf=|usr=}}
{{tp|p=33475702|t=2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.|pdf=|usr=}}
{{tp|p=33475716|t=2021. Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19.|pdf=|usr=}}
{{tp|p=33475701|t=2021. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.|pdf=|usr=}}
{{tp|p=33512398|t=2021. Can We Protect Pregnant Women and Young Infants From COVID-19 Through Maternal Immunization?|pdf=|usr=}}
{{tp|p=33515791|t=2021. Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?|pdf=|usr=}}
{{tp|p=33444566|t=2021. Vitamin D and COVID-19: why the controversy?|pdf=|usr=}}

{{tp|p=33392487|t=2021. Cyclosporine A and COVID19 - The COQUIMA cohort - Author's reply.|pdf=|usr=}}
{{tp|p=33392485|t=2021. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.|pdf=|usr=}}
{{tp|p=33385129|t=2021. Cyclosporine A and COVID-19 - The COQUIMA cohort.|pdf=|usr=}}
{{tp|p=33385128|t=2021. Cyclosporine A and COVID19 - The COQUIMA cohort.|pdf=|usr=}}
{{tp|p=33385124|t=2021. Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials.|pdf=|usr=}}
{{tp|p=33471720|t=2020. Considerations for Gut Microbiota and Probiotics in Patients with Diabetes Amidst the Covid-19 Pandemic: A Narrative Review.|pdf=|usr=}}
{{tp|p=33380209|t=2020. Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients.|pdf=|usr=}}
{{tp|p=33452994|t=2021. Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D.|pdf=|usr=}}
{{tp|p=33413989|t=2020. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial.|pdf=|usr=}}
{{tp|p=33401173|t=2021. A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2.|pdf=|usr=}}
{{tp|p=33387537|t=2021. Urinary trace elements in association with disease severity and outcome in patients with COVID-19.|pdf=|usr=}}
{{tp|p=33447984|t=2021. Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications.|pdf=|usr=}}
{{tp|p=33427370|t=2021. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33520339|t=2020. Lifestyle factors in the prevention of COVID-19.|pdf=|usr=}}
{{tp|p=33387629|t=2021. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.|pdf=|usr=}}
{{tp|p=33408016|t=2021. Can we use hydroxychloroquine to treat COVID-19 now?|pdf=|usr=}}
{{tp|p=33408015|t=2021. Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.|pdf=|usr=}}
{{tp|p=33408014|t=2021. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.|pdf=|usr=}}
{{tp|p=33515771|t=2021. Efficacy of ribavirin and interferon-alpha therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study.|pdf=|usr=}}
{{tp|p=33493690|t=2021. A short discussion about the SARS-CoV-2 mRNA-1273 vaccine.|pdf=|usr=}}
{{tp|p=33476760|t=2021. Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.|pdf=|usr=}}
{{tp|p=33401034|t=2021. Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis.|pdf=|usr=}}
{{tp|p=33385581|t=2021. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study.|pdf=|usr=}}
{{tp|p=33434674|t=2021. Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching.|pdf=|usr=}}
{{tp|p=33437199|t=2021. Clinical characteristics and impacts of traditional Chinese medicine treatment on the convalescents of COVID-19.|pdf=|usr=}}
{{tp|p=33390810|t=2021. DCs-based therapies: potential strategies in severe SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33390800|t=2021. Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy.|pdf=|usr=}}
{{tp|p=33416113|t=2021. Unraveling the roles of vitamin D status and melanin during Covid19 (Review).|pdf=|usr=}}
{{tp|p=33498909|t=2021. Membrane Microvesicles as Potential Vaccine Candidates.|pdf=|usr=}}
{{tp|p=33488318|t=2021. Could Dermaseptin Analogue be a Competitive Inhibitor for ACE2 Towards Binding with Viral Spike Protein Causing COVID19?: Computational Investigation.|pdf=|usr=}}
{{tp|p=33427662|t=2020. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia.|pdf=|usr=}}
{{tp|p=33460304|t=2020. Your help is needed in the fight against COVID-19: Please contribute to the COVID-19 Global Rheumatology Alliance Registry.|pdf=|usr=}}
{{tp|p=33487035|t=2021. The coronavirus disease (COVID-19) - A supportive approach with selected micronutrients.|pdf=|usr=}}
{{tp|p=33425283|t=2021. Ayurvedic metal nanoparticles could be novel antiviral agents against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33488306|t=2020. The Long Haul of COVID-19 Recovery: Immune Rejuvenation versus Immune Support.|pdf=|usr=}}
{{tp|p=33507321|t=2021. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Author's reply.|pdf=|usr=}}
{{tp|p=33388793|t=2021. Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.|pdf=|usr=}}
{{tp|p=33398609|t=2021. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs.|pdf=|usr=}}
{{tp|p=33400161|t=2021. The need for a correct oxygen-ozone autohemotherapy (O3-AHT) in patients with mild to moderate COVID-19 pneumonia.|pdf=|usr=}}
{{tp|p=33400157|t=2021. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.|pdf=|usr=}}
{{tp|p=33390490|t=2021. Immediate Amelioration of Severe Respiratory Distress in Sjogren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab.|pdf=|usr=}}
{{tp|p=33409846|t=2021. Active vitamin D supplementation and COVID-19 infections: review.|pdf=|usr=}}
{{tp|p=33409844|t=2021. Step zero: optimising nutrition for physical and mental health wellbeing during COVID-19.|pdf=|usr=}}
{{tp|p=33433843|t=2021. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?|pdf=|usr=}}
{{tp|p=33490902|t=2021. High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance.|pdf=|usr=}}
{{tp|p=33426509|t=2021. A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening.|pdf=|usr=}}
{{tp|p=33443334|t=2021. Convalescent Whole Blood Donors Screening Strategies for Providing Efficient and Safe COVID-19 Survivors' Plasma and Other Blood Components.|pdf=|usr=}}
{{tp|p=33425697|t=2020. The coronavirus disease 2019 main protease inhibitor from Andrographis paniculata (Burm. f) Ness.|pdf=|usr=}}
{{tp|p=33485650|t=2021. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis.|pdf=|usr=}}
{{tp|p=33482251|t=2021. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.|pdf=|usr=}}
{{tp|p=33440213|t=2021. Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis.|pdf=|usr=}}
{{tp|p=33492492|t=2021. Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus.|pdf=|usr=}}
{{tp|p=33524316|t=2021. SARS-CoV-2 evolution and vaccines: cause for concern?|pdf=|usr=}}
{{tp|p=33521656|t=2021. Divergent effects of acute versus chronic glucocorticoids in COVID-19.|pdf=|usr=}}
{{tp|p=33521667|t=2021. Hydroxychloroquine in the prevention of COVID-19 mortality.|pdf=|usr=}}
{{tp|p=33521676|t=2021. Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 - Authors' reply.|pdf=|usr=}}
{{tp|p=33521675|t=2021. Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19.|pdf=|usr=}}
{{tp|p=33521674|t=2021. Efficacy matters: broadening complement inhibition in COVID-19.|pdf=|usr=}}
{{tp|p=33521673|t=2021. Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply.|pdf=|usr=}}
{{tp|p=33521663|t=2020. Mavrilimumab for severe COVID-19 - Authors' reply.|pdf=|usr=}}
{{tp|p=33521662|t=2020. Mavrilimumab for severe COVID-19.|pdf=|usr=}}
{{tp|p=33521661|t=2020. Mavrilimumab for severe COVID-19.|pdf=|usr=}}
{{tp|p=33521660|t=2020. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33521666|t=2020. GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?|pdf=|usr=}}
{{tp|p=33491234|t=2021. A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.|pdf=|usr=}}
{{tp|p=33459118|t=2021. Antibodies to watch in 2021.|pdf=|usr=}}
{{tp|p=33520672|t=2021. FDA Recommended Potent Drugs against Covid-19: Insight through Molecular Docking.|pdf=|usr=}}
{{tp|p=33521747|t=2021. A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice.|pdf=|usr=}}
{{tp|p=33521295|t=2021. Unresolved questions about the treatment of COVID-19 with corticosteroids.|pdf=|usr=}}
{{tp|p=33521297|t=2020. Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.|pdf=|usr=}}
{{tp|p=33521304|t=2020. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.|pdf=|usr=}}
{{tp|p=33521302|t=2020. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.|pdf=|usr=}}
{{tp|p=33521623|t=2021. AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate.|pdf=|usr=}}
{{tp|p=33520634|t=2021. Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?|pdf=|usr=}}
{{tp|p=33460213|t=2021. What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.|pdf=|usr=}}
{{tp|p=33519030|t=2020. Nutricion y pandemia de la COVID-19.|pdf=|usr=}}
{{tp|p=33524563|t=2021. Inhibitory efficiency of potential drugs against SARS-CoV-2 by blocking human angiotensin converting enzyme-2: Virtual screening and molecular dynamics study.|pdf=|usr=}}
{{tp|p=33520405|t=2021. Small interfering RNA: a tailored approach to explore the therapeutic potential in COVID-19.|pdf=|usr=}}
{{tp|p=33523609|t=2021. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.|pdf=|usr=}}
{{tp|p=33509749|t=2021. [Mechanism and material basis of Lianhua Qingwen capsule for improving clinical cure rate of COVID-19: a study based on network pharmacology and molecular docking technology].|pdf=|usr=}}
{{tp|p=33497482|t=2021. Germicidal UV Sources and Systems(dagger).|pdf=|usr=}}
{{tp|p=33438214|t=2021. Bare-bulb Upper-Room Germicidal Ultraviolet-C (GUV) Indoor Air Disinfection for COVID-19(dagger).|pdf=|usr=}}
{{tp|p=33511704|t=2021. Spices and herbs: Potential antiviral preventives and immunity boosters during COVID-19.|pdf=|usr=}}
{{tp|p=33452734|t=2021. Exploring the treatment of COVID-19 with Yinqiao powder based on network pharmacology.|pdf=|usr=}}
{{tp|p=33448101|t=2021. In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro).|pdf=|usr=}}
{{tp|p=33524017|t=2021. A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.|pdf=|usr=}}
{{tp|p=33524041|t=2021. Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.|pdf=|usr=}}
{{tp|p=33427193|t=2021. Nutritional knowledge, attitude and behaviours regarding Coronavirus Disease 2019 among residents of Gonabad, Iran.|pdf=|usr=}}
{{tp|p=33416888|t=2021. Rapid recovery of taste and smell in a patient with SARS-CoV-2 following convalescent plasma therapy.|pdf=|usr=}}
{{tp|p=33482671|t=2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Allgemeine Aspekte von Allergien auf Impfstoffe, immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen, Teil 2: Charakteristiken der mRNA-Impfstoffe BNT162b2 und mRNA-1273 zur Prophylaxe von COVID-19 und assoziierte Immunphanomene, Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.|pdf=|usr=}}
{{tp|p=33524996|t=2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Allgemeine Aspekte von Allergien auf Impfstoffe, immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen; Teil 2: Charakteristiken der mRNA-Impfstoffe BNT162b2 und mRNA-1273 zur Prophylaxe von COVID-19, weitere Impfstoff-Kandidaten und assoziierte Immunphanomene; Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.|pdf=|usr=}}
{{tp|p=33429407|t=2020. Timing of remdesivir for COVID-19.|pdf=|usr=}}
{{tp|p=33443491|t=2020. Remdesivir (Veklury) for COVID-19.|pdf=|usr=}}
{{tp|p=33443490|t=2020. An EUA for bamlanivimab - a monoclonal antibody for COVID-19.|pdf=|usr=}}
{{tp|p=33451175|t=2020. An EUA for baricitinib (Olumiant) for COVID-19.|pdf=|usr=}}
{{tp|p=33451174|t=2020. An EUA for casirivimab and imdevimab for COVID-19.|pdf=|usr=}}
{{tp|p=33393116|t=2021. Therapeutic targets and potential agents for the treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33382060|t=2020. Terapias celulares para el COVID-19: Una revision sistematica viva.|pdf=|usr=}}
{{tp|p=33397236|t=2021. A mini review on emerging targets and Approaches for the synthesis of Anti-Viral compounds: In perspective to COVID-19.|pdf=|usr=}}
{{tp|p=33405340|t=2021. QSAR Modeling of SARS-CoV M(pro) Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33513050|t=2021. How IvIg Can Mitigate Covid-19 Disease: A Symmetrical Immune Network Model.|pdf=|usr=}}
{{tp|p=33400280|t=2020. Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33400277|t=2020. Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33432224|t=2021. Hunt for improved monoclonals against coronavirus gathers pace.|pdf=|usr=}}
{{tp|p=33432247|t=2021. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent.|pdf=|usr=}}
{{tp|p=33494096|t=2021. Global absence and targeting of protective immune states in severe COVID-19.|pdf=|usr=}}
{{tp|p=33514888|t=2021. How to redesign COVID vaccines so they protect against variants.|pdf=|usr=}}
{{tp|p=33510489|t=2021. Novavax offers first evidence that COVID vaccines protect people against variants.|pdf=|usr=}}
{{tp|p=33471372|t=2021. Extreme Exposure to Filtered Far-UVC: A Case Study.|pdf=|usr=}}
{{tp|p=33389761|t=2021. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial.|pdf=|usr=}}
{{tp|p=33507610|t=2021. Phytotherapeutic options for the treatment of COVID-19: A concise viewpoint.|pdf=|usr=}}
{{tp|p=33452160|t=2021. Vitamin D and COVID-19: causal factor or bystander?|pdf=|usr=}}

{{tp|p=33434117|t=2021. Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19.|pdf=|usr=}}
{{tp|p=33487918|t=2020. Convalescent plasma therapy in COVID 19: Every dark cloud has a silver lining.|pdf=|usr=}}
{{tp|p=33413968|t=2021. 'BhAVI-23'-A spice-herb based dietary infusion possessing in-vitro anti-viral potential.|pdf=|usr=}}
{{tp|p=33491541|t=2021. Drivers of Infectious Disease Seasonality: Potential Implications for COVID-19.|pdf=|usr=}}
{{tp|p=33495424|t=2020. The prognosis and short-term efficacy of corticosteroid therapy for COVID-19 patients.|pdf=|usr=}}
{{tp|p=33397223|t=2021. Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV.|pdf=|usr=}}
{{tp|p=33397209|t=2021. Molecular mechanism of inhibition of COVID-19 main protease by beta-adrenoceptor agonists and adenosine deaminase inhibitors using in silico methods.|pdf=|usr=}}
{{tp|p=33478342|t=2021. In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33475021|t=2021. In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase.|pdf=|usr=}}
{{tp|p=33459192|t=2021. An in silico analysis of Ibuprofen enantiomers in high concentrations of sodium chloride with SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33459182|t=2021. Identification of 1,2,3-triazole-phthalimide derivatives as potential drugs against COVID-19: a virtual screening, docking and molecular dynamic study.|pdf=|usr=}}
{{tp|p=33446077|t=2021. Prospecting for Cressa cretica to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33446058|t=2021. Bacillus species; a potential source of anti-SARS-CoV-2 main protease inhibitors.|pdf=|usr=}}
{{tp|p=33438525|t=2021. Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an in silico drug repurposing study.|pdf=|usr=}}
{{tp|p=33427588|t=2021. Predictive medicinal metabolites from Momordica dioica against comorbidity related proteins of SARS-CoV-2 infections.|pdf=|usr=}}
{{tp|p=33382023|t=2020. Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study.|pdf=|usr=}}
{{tp|p=33382021|t=2020. Virtual repurposing of ursodeoxycholate and chenodeoxycholate as lead candidates against SARS-Cov2-Envelope protein: A molecular dynamics investigation.|pdf=|usr=}}
{{tp|p=33423911|t=2021. Successful Management of COVID-19 With Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient.|pdf=|usr=}}
{{tp|p=33426541|t=2020. Potentials of Interferons and Hydroxychloroquine for the Prophylaxis and Early Treatment of COVID-19.|pdf=|usr=}}
{{tp|p=33468620|t=2021. Ipomoeassin-F inhibits the in vitro biogenesis of the SARS-CoV-2 spike protein and its host cell membrane receptor.|pdf=|usr=}}
{{tp|p=33474624|t=2021. C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.|pdf=|usr=}}
{{tp|p=33458752|t=2020. Relationship Between Dietary Variety and Frailty in Older Japanese Women During the Period of Restriction on Outings Due to COVID-19.|pdf=|usr=}}
{{tp|p=33476835|t=2021. Convalescent plasma: Alternative or promising therapy?|pdf=|usr=}}
{{tp|p=33460844|t=2021. Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33385588|t=2021. Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.|pdf=|usr=}}
{{tp|p=33441177|t=2021. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.|pdf=|usr=}}
{{tp|p=33426096|t=2020. Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs.|pdf=|usr=}}
{{tp|p=33402301|t=2021. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19.|pdf=|usr=}}
{{tp|p=33493919|t=2021. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.|pdf=|usr=}}
{{tp|p=33493917|t=2021. The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions.|pdf=|usr=}}
{{tp|p=33486372|t=2021. Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2.|pdf=|usr=}}
{{tp|p=33509217|t=2021. Anti-inflammatory potential of Quercetin in COVID-19 treatment.|pdf=|usr=}}
{{tp|p=33447071|t=2021. Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review.|pdf=|usr=}}
{{tp|p=33414643|t=2020. Calcio-Herbal Medicine Divya-Swasari-Vati Ameliorates SARS-CoV-2 Spike Protein-Induced Pathological Features and Inflammation in Humanized Zebrafish Model by Moderating IL-6 and TNF-alpha Cytokines.|pdf=|usr=}}
{{tp|p=33433387|t=2021. Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines.|pdf=|usr=}}
{{tp|p=33393485|t=2021. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.|pdf=|usr=}}
{{tp|p=33432258|t=2021. Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: Molecular docking and DFT calculations.|pdf=|usr=}}
{{tp|p=33390681|t=2021. Computational investigations of three main drugs and their comparison with synthesized compounds as potent inhibitors of SARS-CoV-2 main protease (M(pro)): DFT, QSAR, molecular docking, and in silico toxicity analysis.|pdf=|usr=}}
{{tp|p=33463095|t=2021. The Impact of the Coronavirus Disease-2019 Pandemic on Childhood Obesity and Vitamin D Status.|pdf=|usr=}}
{{tp|p=33425294|t=2020. Computational Biology Analysis of COVID-19 Receptor-Binding Domains: A Target Site for Indocyanine Green Through Antimicrobial Photodynamic Therapy.|pdf=|usr=}}
{{tp|p=33425284|t=2020. Application of Laser Blue Light With a Wavelength of 405 nm in the Treatment of Patients With the Virus COVID-19.|pdf=|usr=}}
{{tp|p=33500211|t=2021. Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?|pdf=|usr=}}
{{tp|p=33390633|t=2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part I: Complexation with iodine in different solvents.|pdf=|usr=}}
{{tp|p=33390634|t=2021. Excited-state electronic properties, structural studies, noncovalent interactions, and inhibition of the novel severe acute respiratory syndrome coronavirus 2 proteins in Ripretinib by first-principle simulations.|pdf=|usr=}}
{{tp|p=33500591|t=2021. Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease.|pdf=|usr=}}
{{tp|p=33390613|t=2021. Synthesis of novel indolo[3,2-c]isoquinoline derivatives bearing pyrimidine, piperazine rings and their biological evaluation and docking studies against COVID-19 virus main protease.|pdf=|usr=}}
{{tp|p=33424034|t=2021. Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico / in vitro assessment.|pdf=|usr=}}
{{tp|p=33457350|t=2020. Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India.|pdf=|usr=}}
{{tp|p=33493945|t=2021. Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk.|pdf=|usr=}}
{{tp|p=33437230|t=2021. In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants.|pdf=|usr=}}
{{tp|p=33443088|t=2021. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.|pdf=|usr=}}
{{tp|p=33497729|t=2021. Antiviral activity of bioactive phytocompounds against coronavirus: An update.|pdf=|usr=}}
{{tp|p=33417058|t=2021. A case of shock after 10 days systemic corticosteroid therapy for COVID-19.|pdf=|usr=}}
{{tp|p=33478708|t=2021. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.|pdf=|usr=}}
{{tp|p=33427208|t=2021. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.|pdf=|usr=}}
{{tp|p=33476300|t=2021. Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.|pdf=|usr=}}
{{tp|p=33520251|t=2021. Chloroquine and COVID-19: role as a bitter taste receptor agonist?|pdf=|usr=}}
{{tp|p=33518950|t=2020. Can vitamin D offer protection against the coronavirus?|pdf=|usr=}}
{{tp|p=33494567|t=2021. Vitamin D in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with non-invasive ventilation support.|pdf=|usr=}}
{{tp|p=33520633|t=2021. In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex.|pdf=|usr=}}
{{tp|p=33520632|t=2021. Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus.|pdf=|usr=}}
{{tp|p=33518780|t=2021. inverted question markEs la nutricion el factor de riesgo olvidado en la infeccion por COVID-19?|pdf=|usr=}}
{{tp|p=33519022|t=2021. Principales desafios del desequilibrio electrolitico en pacientes geriatricos con COVID-19 y riesgo de prolongacion del intervalo QT.|pdf=|usr=}}
{{tp|p=33382930|t=2020. Mega doses of retinol: A possible immunomodulation in Covid-19 illness in resource-limited settings.|pdf=|usr=}}
{{tp|p=33515320|t=2021. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis.|pdf=|usr=}}
{{tp|p=33502499|t=2021. Baricitinib set to join the Covid-19 therapeutic arsenal?|pdf=|usr=}}
{{tp|p=33519274|t=2021. Fighting against the second wave of COVID-19: Can honeybee products help protect against the pandemic?|pdf=|usr=}}
{{tp|p=33519272|t=2021. In-silico network-based analysis of drugs used against COVID-19: Human well-being study.|pdf=|usr=}}
{{tp|p=33519276|t=2021. In silico prediction and experimental validation of siRNAs targeting ORF1ab of MERS-CoV in Vero cell line.|pdf=|usr=}}
{{tp|p=33519275|t=2021. Potential bangle (Zingiber montanum J.Konig) rhizome extract as a supplement to prevent and reduce symptoms of Covid-19.|pdf=|usr=}}
{{tp|p=33519339|t=2021. Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.|pdf=|usr=}}
{{tp|p=33519336|t=2021. Convalescent Plasma in COVID-19: To what Degree should Clinicians Rely on Currently Available Data?|pdf=|usr=}}
{{tp|p=33397677|t=2021. Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals.|pdf=|usr=}}
{{tp|p=33514629|t=2021. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.|pdf=|usr=}}
{{tp|p=33495306|t=2021. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.|pdf=|usr=}}
{{tp|p=33495308|t=2021. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.|pdf=|usr=}}
{{tp|p=33495307|t=2021. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.|pdf=|usr=}}
{{tp|p=33436526|t=2021. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.|pdf=|usr=}}
{{tp|p=33436524|t=2021. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.|pdf=|usr=}}
{{tp|p=33516820|t=2021. Edible plant-derived exosomal microRNAs: Exploiting a cross-kingdom regulatory mechanism for targeting SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33483756|t=2021. Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.|pdf=|usr=}}
{{tp|p=33518427|t=2021. COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review.|pdf=|usr=}}
{{tp|p=33518428|t=2021. WITHDRAWN: New Generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.|pdf=|usr=}}
{{tp|p=33458811|t=2021. COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors.|pdf=|usr=}}
{{tp|p=33448402|t=2021. Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial.|pdf=|usr=}}
{{tp|p=33521322|t=2021. Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients.|pdf=|usr=}}
{{tp|p=33523551|t=2021. Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD.|pdf=|usr=}}
{{tp|p=33519087|t=2021. Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic.|pdf=|usr=}}
{{tp|p=33519086|t=2020. Food policy, nutrition and nutraceuticals in the prevention and management of COVID-19: Advice for healthcare professionals.|pdf=|usr=}}
{{tp|p=33522946|t=2021. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL).|pdf=|usr=}}
{{tp|p=33516600|t=2021. Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.|pdf=|usr=}}
{{tp|p=33524990|t=2021. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.|pdf=|usr=}}
{{tp|p=33481519|t=2021. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).|pdf=|usr=}}
{{tp|p=33481518|t=2021. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).|pdf=|usr=}}
{{tp|p=33411888|t=2021. Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development.|pdf=|usr=}}
{{tp|p=33401979|t=2021. Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase.|pdf=|usr=}}
{{tp|p=33423931|t=2021. Copper in infectious disease: Using both sides of the penny.|pdf=|usr=}}
{{tp|p=33482680|t=2021. Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-analysis.|pdf=|usr=}}
{{tp|p=33443365|t=2021. H2S As A Therapeutic Adjuvant Against COVID-19: Why and How?|pdf=|usr=}}
{{tp|p=33448169|t=2020. [Mechanism and intervention of mucosal immune regulation based on "lung and large intestine being interior-exteriorly related" theory of traditional Chinese medicine].|pdf=|usr=}}
{{tp|p=33415866|t=2020. [Effect of moxibustion on clinical symptoms, peripheral inflammatory indexes and T lymphocyte subsets in COVID-19 patients].|pdf=|usr=}}
{{tp|p=33496147|t=2020. [Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection].|pdf=|usr=}}
{{tp|p=33463485|t=2020. [Effectiveness of convalescent plasma for treatment of coronavirus disease 2019 patients].|pdf=|usr=}}